International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN (this applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation, such as low-molecular-weight heparin or warfarin, should be on a stable dose), within 2 weeks of randomizationXx_NEWLINE_xXPatients who are currently receiving therapeutic anticoagulants (including aspirin, low molecular weight heparin, and others) are not eligibleXx_NEWLINE_xXPatients must not have evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted; the clinical indication for therapeutic anticoagulation must be clearly documented prior to enrollment and must be discussed with the principal investigator (PI); patients on greater than or equal to 2 anti-thrombotic agents, including but not limited to anti-platelet agents (nonsteroidal anti-inflammatory drugs [NSAIDS]/aspirin, clopidogrel), heparin, low molecular weight heparin, warfarin and a direct thrombin inhibitor will be excludedXx_NEWLINE_xXNo concurrent anticoagulation with warfarin or heparin/heparin analogues, clopidogrel, oral direct thrombin inhibitors, or direct factor XA inhibitorsXx_NEWLINE_xXPatient must not require the use of full dose coumarin-derivative anticoagulants such as warfarin; low molecular weight heparin is permitted for prophylactic or therapeutic use; factor X inhibitors are permitted\r\n* NOTE: Warfarin may not be started while enrolled in the EAY131 study\r\n* Stopping the anticoagulation for biopsy should be per site standard operating procedure (SOP)Xx_NEWLINE_xXPatients must not have any serious or unstable pre-existing medical conditions (aside from malignancy exceptions specified above), including but not limited to, ongoing or active infection requiring parenteral antibiotics on day 1, history of bleeding diathesis or need for concurrent anticoagulation (international normalized ratio [INR] =< 1.5 and partial thromboplastin time [PTT] within 1.1 x ULN), or psychiatric illness/social situations that would limit compliance with study requirements, interfere with subject’s safety, or obtaining informed consent; therapeutic level dosing of warfarin can be used with close monitoring of prothrombin time (PT)/INR by the site; exposure may be decreased due to enzyme induction when on treatment, thus warfarin dosing may need to be adjusted based upon PT/INR; consequently, when discontinuing dabrafenib, warfarin exposure may be increased and thus close monitoring via PT/INR and warfarin dose adjustments must be made as clinically appropriate; prophylactic low dose warfarin may be given to maintain central catheter patencyXx_NEWLINE_xXNo concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, low molecular weight heparin (LMWH), thrombin or factor Xa inhibitors, or antiplatelet agents (e.g., clopidogrel); (low dose aspirin [=< 81 mg/day] and prophylactic LMWH are permitted)Xx_NEWLINE_xXNo concomitant anticoagulation with oral anticoagulants (e.g., warfarin, direct thrombin and Factor Xa inhibitors) or platelet inhibitors (e.g., clopidogrel); allowed anticoagulants are the following:\r\n* Low-dose aspirin for cardioprotection (per local applicable guidelines) is permitted\r\n* Low molecular weight heparins (LMWH) or unfractionated heparin is permitted\r\n* Anticoagulation with therapeutic doses of LMWH is allowed in subjects without known brain metastases who are on a stable dose of LMWH for at least 6 weeks before first dose of study treatment, and who have had no clinically significant hemorrhagic complications from the anticoagulation regimen or the tumorXx_NEWLINE_xXInternational normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN (or on stable dose of therapeutic anticoagulation, such as low-molecular-weight heparin, warfarin or rivaroxaban)Xx_NEWLINE_xXPatients must be able and willing to receive prophylaxis with daily aspirin, low molecular weight heparin, factor X inhibitors or warfarin if randomized to lenalidomide; patients must also be willing to receive pneumocystis jirovecii prophylaxis with sulfamethoxazole/trimethoprim, dapsone, atovaquone or inhaled pentamidine, in the event that they are randomized to TGR-1202; patients unable or unwilling to take any listed prophylaxis are NOT eligibleXx_NEWLINE_xXConcomitant anticoagulation with oral anticoagulants (e.g., warfarin, direct thrombin, and Factor Xa inhibitors) or platelet inhibitors (e.g., clopidogrel) are prohibited\r\n* Note: Low-dose aspirin for cardioprotection (per local applicable guidelines) and low dose, low molecular weight heparins (LMWH) are permitted; anticoagulation with therapeutic doses of LMWH is allowed in subjects without radiographic evidence of brain metastasis, who are on a stable dose of LMWH for at least 6 weeks before first dose of study treatment, and who have had no complications from a thromboembolic event or the anticoagulation regimenXx_NEWLINE_xXInternational normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN (this applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation, such as low-molecular-weight heparin or warfarin, should be on a stable dose)Xx_NEWLINE_xXNeed for anticoagulationXx_NEWLINE_xXPatient is currently receiving warfarin or other coumarin-derived anticoagulant for treatment, prophylaxis or otherwise; therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowedXx_NEWLINE_xXPatients requiring warfarin are not eligibleXx_NEWLINE_xXPatients who require anticoagulation with warfarin or equivalent vitamin K antagonists are not eligibleXx_NEWLINE_xXCurrent necessity for full-dose anticoagulation with warfarin or its equivalent (i.e. unfractionated and/or low molecular weight heparin)Xx_NEWLINE_xXPatients receiving full dose anticoagulation therapy (e.g., warfarin or low molecular weight [LMW] heparin) and does not meet both of the following criteria: \r\n* No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)\r\n* In-range international normalized ratio (INR) (usually between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparinXx_NEWLINE_xXPatient is currently receiving warfarin or other coumadin-derived anticoagulant for treatment, prophylaxis or otherwise; therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowed as long as patient has adequate coagulation defined as: activated partial thromboplastin time (aPTT) international normalized ratio (INR) =< 1.5 x upper limit of normalXx_NEWLINE_xXINR or prothrombin time (PT) < 1.5 x the ULN except for patients receiving anticoagulation, who must be on a stable dose of warfarin for 6 weeks prior to enrollmentXx_NEWLINE_xXConcurrent use of warfarinXx_NEWLINE_xXParticipants may not be currently receiving anticoagulation with coumadin for treatment or prophylaxis; therapy with heparin, low molecular weight heparin (LMWH), or fondaparinux is allowedXx_NEWLINE_xXTreatment with anticoagulation with warfarin, low-molecular-weight heparin, or similar agents for therapeutic purposes;Xx_NEWLINE_xXCurrently receiving warfarin or other warfarin-derived anticoagulant for treatment, prophylaxis or otherwise; Note: Therapy with heparin, direct oral anticoagulants, low molecular weight heparin (LMWH) or fondaparinux is allowedXx_NEWLINE_xXTreatment with systemic anticoagulation (e.g. warfarin, heparin, low molecular weight heparin, anti-Xa inhibitors, etc.) except aspirinXx_NEWLINE_xXRequired concurrent use of anti-coagulants or anti-platelet medication, with the exception of aspirin doses ?81 mg/day, low-dose SC heparin or SC low-molecular-weight heparin for DVT prophylaxis, or heparin flushes to maintain IV catheter patencyXx_NEWLINE_xXInternational normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN (this applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation, such as low-molecular-weight heparin or warfarin, should be on a stable dose)Xx_NEWLINE_xXSubjects on active anticoagulation therapy including warfarin, factor Xa inhibitors, thrombin inhibitors, or heparin.Xx_NEWLINE_xXTherapeutic anticoagulation with vitamin-K antagonists (e.g., warfarin) or with heparins and heparinoids; however, prophylactic anticoagulation as described below is allowed:\r\n* Low dose warfarin (1 mg orally, once daily) with prothrombin time (PT)-INR =< 1.5 x ULN is permitted; infrequent bleeding or elevations in PT-INR have been reported in some subjects taking warfarin while on regorafenib therapy; therefore, subjects taking concomitant warfarin should be monitored regularly for changes in PT, PT-INR or clinical bleeding episodes\r\n* Low dose aspirin (=< 100 mg daily)\r\n* Prophylactic doses of heparinXx_NEWLINE_xXPatient is currently receiving warfarin or other coumarin-derived anticoagulant for treatment, prophylaxis or otherwise; therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowedXx_NEWLINE_xXAny patients on warfarin therapyXx_NEWLINE_xXPatient is currently receiving warfarin or other Coumadin-derived anticoagulant for treatment, prophylaxis or otherwise; therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowedXx_NEWLINE_xXPatient is currently receiving warfarin or other coumarin-derived anticoagulant for treatment, prophylaxis or otherwise; therapy with heparin, direct thrombin inhibitors, low molecular weight heparin (LMWH) or fondaparinux is allowedXx_NEWLINE_xXFor patients with platelets > 100,000 cells/ul (100x10^9/L) able to take aspirin daily as prophylactic anticoagulation therapy for ARMS 2+3 (patients intolerant to aspirin may use warfarin, low-molecular-weight heparin or equivalent anti-platelet therapy)Xx_NEWLINE_xXAnticoagulation and anti-platelet therapies are not permitted (this includes Coumadin, low molecular weight heparins, factor Xa inhibitors, aspirin and non-steroidal anti-inflammatory drug [NSAIDS] or other medicines with similar effects)Xx_NEWLINE_xXThe subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or factor Xa inhibitors, or antiplatelet agents (e.g., clopidogrel); low dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are permittedXx_NEWLINE_xXConcomitant anticoagulation at therapeutic doses with oral anticoagulants or platelet inhibitorsXx_NEWLINE_xXThe following concomitant medications are not allowed during navitoclax administration: clopidogrel, ibuprofen, tirofiban, warfarin, and other anticoagulants, drugs, or herbal supplements that affect platelet function are excluded, with the exception of low-dose anticoagulation medications (such as heparin) that are used to maintain the patency of a central intravenous catheter; aspirin will not be allowed within 7 days prior to the first dose of navitoclax or during navitoclax administration; however, subjects who have previously received aspirin therapy for thrombosis prevention may resume a low dose (i.e., maximum 100 mg QD) of aspirin if platelet counts are stable (>= 50,000/mm^3) through 6 weeks of navitoclax administration; all decisions regarding treatment with aspirin therapy will be determined by the investigator in conjunction with the medical monitorXx_NEWLINE_xXTherapeutic anticoagulation is allowed; the participant must be on a stable dose of anticoagulant medication (warfarin, or low molecular weight heparin [LMWH]) prior to study entryXx_NEWLINE_xXPatients may NOT be on full dose anti-coagulation therapy; maintenance doses of low molecular weight heparin is permissibleXx_NEWLINE_xXPatients taking warfarin are not eligible; patients on therapeutic doses of anticoagulants are excluded from studyXx_NEWLINE_xXPatients with contraindications to any of the required concomitant drugs or supportive treatments, including hypersensitivity to anticoagulation and antiplatelet options, antiviral drugs; for example, patients with a prior history of thrombotic disease who also have a contraindication to full anticoagulation including warfarin or low molecular weight heparin, would be excludedXx_NEWLINE_xXContraindication to any of the required concomitant drugs, including proton-pump inhibitor (e.g. lansoprazole), enteric-coated aspirin or if a history of prior thrombotic disease, warfarin or low molecular weight heparinXx_NEWLINE_xXCurrent and continuing anticoagulation with warfarin sodium (Coumadin, heparin, low-molecular weight heparin, Clopidogrel bisulfate (Plavix),or equivalent. (Unless it can be stopped to manage treatment related toxicity, to have a biopsy if needed, or for marker placement).Xx_NEWLINE_xXPatients who are not already on anticoagulation should be able to take low-dose aspirin (81 mg) daily; NOTE: if aspirin is contraindicated for other reasons, the patient may be considered for the study after consultation with the study chair regarding other alternatives including possible use of warfarin or low molecular weight heparin; patients unable to take any form of prophylaxis are not eligibleXx_NEWLINE_xXConcomitant anticoagulation at therapeutic doses with oral anticoagulants (eg, warfarin, direct thrombin and factor Xa inhibitors) or platelet inhibitors (eg, clopidogrel)\r\n* Note: Low-dose aspirin for cardioprotection (per local applicable guidelines), low-dose warfarin (< 1 mg/day), and low dose, low molecular weight heparins (LMWH) are permitted. Anticoagulation with therapeutic doses of LMWH is allowed in subjects without radiographic evidence of brain metastasis, who are on a stable dose of LMWH for at least 12 weeks before randomization, and who have had no complications from a thromboembolic event or the anticoagulation regimenXx_NEWLINE_xXPatients who are on therapeutic anticoagulation with warfarin; patients on therapeutic doses of with low molecular weight heparins are eligibleXx_NEWLINE_xXInternational normalized ratio (INR) and partial thromboplastin time (aPTT) =< 1.5 x ULN (this applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation, such as low-molecular-weight heparin or warfarin, should be on a stable dose)Xx_NEWLINE_xXParticipants should not take drugs that directly and durably inhibit coagulation with the exception of warfarin (coumadin) and heparin including low-molecular-weight heparin (LMWH), including enoxaparin, tinzaparin, etcXx_NEWLINE_xXAdequate coagulation function as defined by International Normalized Ratio (INR) =< 1.5 and partial thromboplastin time (PTT) =< 5 seconds above the ULN (unless receiving anticoagulation therapy); patients receiving warfarin must be switched to low molecular weight heparin and have achieved stable coagulation profile prior to first dose of protocol therapyXx_NEWLINE_xXconcomitant use of therapeutic anticoagulationXx_NEWLINE_xXPatient is currently receiving warfarin or other coumadin-derived anticoagulant for treatment, prophylaxis or otherwise; therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowedXx_NEWLINE_xXPatients who require concurrent treatment with antithrombotic and/or anti-platelet agents (e.g., warfarin, heparin, low molecular weight heparin, aspirin, and/or ibuprofen)Xx_NEWLINE_xXAnticoagulation with low-molecular-weight heparin (LMWH) will be permitted; patients receiving treatment with warfarin or any of the new oral anticoagulants (NOACs) (rivaroxaban, apixaban, dabigatran, or edoxaban) will be given the option to switch to LMWHXx_NEWLINE_xXfor subjects receiving anticoagulant, the subjects must, in the investigator's opinion, be clinically stable with no evidence of active bleeding while receiving anticoagulant therapy. The INR for subjects on warfarin should be in the therapeutic range. Low molecular weight heparin (LMWH) is allowed.Xx_NEWLINE_xXPatients must not be on therapeutic anticoagulation (Warfarin [coumadin] and/or low molecular weight heparin are prohibited). Prophylactic anticoagulation (i.e. intraluminal heparin) of venous or arterial access devices is allowed.Xx_NEWLINE_xXPatients who are currently receiving therapeutic anti-coagulation with heparin, low-molecular weight heparin or Coumadin are not eligible for this trialXx_NEWLINE_xXThe participant requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or factor xabans (Xa) inhibitors, or antiplatelet agents (e.g., clopidogrel); low dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are permittedXx_NEWLINE_xXPatients being treated with Warfarin.Xx_NEWLINE_xXConcomitant use of warfarin or other vitamin K antagonistsXx_NEWLINE_xXConcomitant use of warfarin or other vitamin K antagonistsXx_NEWLINE_xXThe patient requires therapeutic doses of any anticoagulant, including low molecular weight heparin (LMWH). Concomitant use of warfarin, even at prophylactic doses, is prohibited.Xx_NEWLINE_xXPatient is currently receiving warfarin or other coumarin derived anti-coagulant, for treatment, prophylaxis or otherwise; therapy with heparin, low molecular weight heparin (LMWH), fondaparinux, or other oral anticoagulants is allowedXx_NEWLINE_xXRequires continued use of warfarin for anticoagulation and cannot stop warfarin to be safely switched to another anticoagulantXx_NEWLINE_xXAble to take a minimum dose of aspirin 81 mg daily as prophylactic anticoagulation if not on warfarin, low molecular weight heparin or oral factor Xa inhibitor; patients intolerant to acetylsalicylic acid (ASA) may use warfarin or low molecular weight heparin at doses designed to treat deep venous thrombosisXx_NEWLINE_xXHeparin, warfarin or similar anti-coagulants (except. low molecular weight heparin for treatment/prophylaxis) currently or w/in 4 wks of study drugXx_NEWLINE_xXTherapeutic anticoagulation with vitamin-K antagonists (e.g., warfarin) or with heparins and heparinoids\r\n* However, prophylactic anticoagulation as described below is allowed:\r\n** Low dose warfarin (1 mg orally, once daily) with PT-INR =< 1.5 x ULN is permitted; subjects taking concomitant warfarin should be monitored regularly for changes in PT, PT-INR or clinical bleeding episodes\r\n** Low dose aspirin (=< 100 mg daily)\r\n** Prophylactic doses of heparinXx_NEWLINE_xXPatients taking warfarin; if anticoagulation is required, the patient must be on a stable dose of a Food and Drug Administration (FDA) approved anticoagulant other than warfarin (e.g. enoxaparin, dalteparin, fondaparinux, apixaban, rivaroxaban) for at least 30 daysXx_NEWLINE_xXTherapeutic anticoagulation with vitamin-K antagonists (e.g., warfarin) or with heparins and heparinoids\r\n* However, prophylactic anticoagulation as described below is allowed:\r\n** Low dose warfarin (1 mg orally, once daily) with PT-INR =< 1.5 x ULN is permitted; infrequent bleeding or elevations in PT-INR have been reported in some subjects taking warfarin while on regorafenib therapy; therefore, subjects taking concomitant warfarin should be monitored regularly for changes in PT, PT-INR or clinical bleeding episodes\r\n** Low dose aspirin (=< 100 mg daily)\r\n** Prophylactic doses of heparinXx_NEWLINE_xXTreatment with warfarin or other vitamin K antagonists (eg, phenprocoumon)Xx_NEWLINE_xXPatients must not be receiving systemic anticoagulation with warfarin; patients must be off warfarin for 30 days prior to enrollment; patients who require anticoagulation with an agent other than warfarin will not be excluded, but must be reviewed by the principal investigator prior to enrollmentXx_NEWLINE_xXRequire therapeutic use of anticoagulation medicationsXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5; (anticoagulation with low molecular weight heparin is allowed if on a stable dose for > 2 weeks at time of enrollment)Xx_NEWLINE_xXRequirement of therapeutic anticoagulant therapy with oral vitamin K antagonists; low-dose anticoagulants for maintenance of patency of central venous access devise or prevention of deep venous thrombosis is allowed; therapeutic use of low molecular weight heparin (or similar parenteral drug) for venous-thromboembolic disease is allowedXx_NEWLINE_xXUse of anticoagulants (e.g., warfarin, heparin) at therapeutic levels within 7 days prior to the first dose of GSK525762. Low dose (prophylactic) low molecular weight heparin (LMWH) is permitted. In addition, INR must be monitored in accordance with local institutional practices, as appropriate.Xx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program; able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to acetylsalicylic acid [ASA] may use warfarin or low molecular weight heparin)Xx_NEWLINE_xXIf they are on any dose of warfarin or are on full dose anticoagulation with other agents, including low molecular weight heparin, antithrombin agents, antiplatelet agents and full dose aspirin within 7 days prior to first dose of study drug; patients on prophylactic doses of low-molecular weight heparin are allowedXx_NEWLINE_xXCurrently using warfarin.Xx_NEWLINE_xXPatients on therapeutic doses of Coumadin (> 1 mg daily); the use of therapeutic or prophylactic low molecular weight heparin or fragmin is permittedXx_NEWLINE_xXCurrent and continuing anticoagulation with warfarin sodium (Coumadin), heparin, low- molecular weight heparin, Clopidogrel bisulfate (Plavix), or equivalent (unless it can be stopped to manage treatment related toxicity or to have a biopsy if needed).Xx_NEWLINE_xXInternational normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN. This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation (such as low-molecular-weight heparin or warfarin) should be on a stable dose.Xx_NEWLINE_xXCurrent and continuing anticoagulation with warfarin sodium (coumadin), heparin, low- molecular weight heparin, Clopidogrel bisulfate (plavix), or equivalent (unless it can be stopped to manage treatment related toxicity, to have a biopsy if needed, or place markers)Xx_NEWLINE_xXRequirement of anticoagulant therapy with oral vitamin K antagonists such as Coumadin (warfarin). Low-dose anticoagulants for the maintenance of patency in a central venous access device or the prevention of deep vein thrombosis or pulmonary embolism is allowed. Therapeutic use of low molecular weight heparin is allowed provided patients are safely able to interrupt it prior to biopsy procedures.Xx_NEWLINE_xXWarfarin (any dose) or full-dose anticoagulation with other agents (low molecular weight heparin, antithrombin agents, anti-platelet agents and full dose aspirin) within 7 days prior to first dose of study drug; patients on prophylactic doses of low-molecular weight heparin are allowedXx_NEWLINE_xXPatient is using warfarin or any other Coumadin-derivative anticoagulant or vitamin K antagonists or any form of anticoagulation including low molecular weight heparinXx_NEWLINE_xXSubject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin-related agents, thrombin or FXa inhibitors, or antiplatelet agents (eg, clopidogrel). Low-dose aspirin (?81 mg/day), low-dose warfarin (?1 mg/day), and prophylactic low molecular weight heparin are permitted.Xx_NEWLINE_xXRequires the use of warfarin (because of potential drug-drug interactions that may potentially increase the exposure of warfarin)Xx_NEWLINE_xXWarfarin use, even if low dose warfarin is not acceptable; however, other anti-coagulants (e.g. aspirin, enoxaparin and heparin derivatives, thrombin inhibitors, etc) are acceptableXx_NEWLINE_xXThe patient is currently on warfarin or heparin therapyXx_NEWLINE_xXUse of full dose, therapeutic anti-coagulation with warfarinXx_NEWLINE_xXRequires anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon); patients may be eligible if able to be taken off warfarin and started on an alternative anticoagulantXx_NEWLINE_xXSubjects who require therapeutic anticoagulation or anti-platelet therapy\r\n* Low dose aspirin (=< 100 mg/day) is allowed\r\n* Prophylactic doses of low molecular weight heparin (LMWH) are allowed if approved by study chair or designeeXx_NEWLINE_xXPatients on therapeutic or prophylactic anticoagulation will be excluded from enrollment on the protocol; however, patients can remain on the study if they develop a thrombosis that requires therapeutic anticoagulation during the course of protocol therapyXx_NEWLINE_xXRequires anticoagulation with warfarin or other vitamin K antagonistsXx_NEWLINE_xXThrombotic disorders or use of anticoagulants, such as warfarin, requiring therapeutic international normalized ratio (INR) monitoring; (treatment with low molecular weight heparin (LMWH) or direct acting oral anti-coagulants is allowed)Xx_NEWLINE_xXRequires therapeutic anticoagulation with warfarin at baseline\r\n* Patients must be off warfarin or warfarin-derivative anti-coagulants for at least 7 days prior to starting study drug, however, therapeutic or prophylactic therapy with low-molecular weight heparin is allowedXx_NEWLINE_xXSTUDY TREATMENT: International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 × ULN within 14 days prior to the first study treatment.\r\n* This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation (such as low-molecular-weight heparin or warfarin) should be on a stable dose.Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 x ULN (this applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation, such as low-molecular-weight heparin or warfarin, should be on a stable dose)Xx_NEWLINE_xXActivated partial thromboplastin time (aPPT) =< 1.5 x ULN (this applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation, such as low-molecular-weight heparin or warfarin, should be on a stable dose)Xx_NEWLINE_xXCurrently receiving anticoagulation therapy with warfarin;Xx_NEWLINE_xXPatients receiving anticoagulation or anti-platelet therapy are excluded; excluded agents include heparin or low molecular weight heparin, warfarin, clopidogrel, ibuprofen and other nonsteroidal anti-inflammatory drug (NSAIDS), tirofiban, and other anticoagulants, drugs, or herbal supplements that affect platelet function; administration of heparin to keep subject's infusion lines patent is allowed; low-dose anticoagulation medications that are used to maintain the patency of a central intravenous catheter are allowed; aspirin will not be allowed within 7 days prior to the first dose of navitoclax or during navitoclax administration; however, subjects who have previously received aspirin therapy for thrombosis prevention, may resume a low dose (i.e., maximum 100 mg QD) of aspirin if platelet counts are stable (>= 50,000/mm^3) through 6 weeks of navitoclax administration; all decisions regarding treatment with aspirin therapy will be determined by the investigator in conjunction with the medical monitorXx_NEWLINE_xXTherapeutic anticoagulation with drugs requiring international normalized ratio (INR) monitoring (except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous devise) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid < 325 mg per day)Xx_NEWLINE_xXConcomitant Medications\r\n* Other planned concurrent investigational agents or other tumor directed therapies (chemotherapy, radiation) are not allowed while on this study\r\n* Concurrent use of somatostatin analogs while on cabozantinib/placebo is allowed provided that the patient has been on a stable dose for at least two months\r\n* Full dose oral anticoagulation/antiplatelet therapy is not permitted; low dose aspirin =< 81 mg/day is allowed; anticoagulation with therapeutic doses of low molecular weight heparin (LMWH) is allowed in patients who are on a stable dose of LMWH for at least 6 weeks prior to registration; treatment with warfarin is not allowed; anticoagulation in patients with brain metastases is not permitted\r\n* Chronic concomitant treatment with strong inhibitors of CYP3A4 is not allowed; patients must discontinue the drug at least 14 days prior to registration on the study\r\n* Chronic concomitant treatment with strong CYP3A4 inducers is not allowed; patients must discontinue the drug at least 14 days prior to the start of study treatmentXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5; anticoagulation is allowed only with low molecular weight heparin (LMWH); patient receiving LMW heparin on stable therapeutic dose for more than 2 weeks or with factor Xa level < 1.1 U/mL are allowed on the trialXx_NEWLINE_xXConcomitant anticoagulation with oral anticoagulants (e.g., warfarin, direct thrombin and Factor Xa inhibitors), platelet inhibitors (e.g., clopidogrel) or therapeutic doses of low molecular weight heparins (LMWH). Low dose aspirin for cardioprotection (per local applicable guidelines) and low-dose LMWH are permitted. Anticoagulation with therapeutic doses of LMWH is allowed in subjects who are on a stable dose of LMWH for at least 6 weeks before the first dose of study treatment, and who have had no clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor.Xx_NEWLINE_xXCurrent anticoagulation therapy with therapeutic doses of warfarin (low-dose warfarin =< 1 mg/day or low molecular-weight heparin are permittedXx_NEWLINE_xXPatients on coumadin must be willing to switch to an alternative subcutaneous low-molecular-weight heparin (LMWH) or oral agent (at principal investigator [PI] discretion exceptions can be permitted, as determined on a case by case basis and documented)Xx_NEWLINE_xXInternational normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN.\r\n* This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation (such as low-molecular-weight heparin or warfarin) should be on a stable dose.Xx_NEWLINE_xXRequires anticoagulation with warfarin or equivalent vitamin K antagonists (e.g. phenprocoumon)Xx_NEWLINE_xXThromboembolic events requiring therapeutic anticoagulation; concomitant anticoagulation with oral anticoagulants (e.g., warfarin, direct thrombin and factor Xa inhibitors), platelet inhibitors (e.g., clopidogrel) are prohibited\r\n* Note: Low-dose aspirin for cardioprotection (per local applicable guidelines) and low-dose low-molecular-weight heparin (LMWH) are permitted (in subjects who are on a stable dose of LMWH for at least 6 weeks before the first dose of study treatment, and who have had no clinically significant hemorrhagic complications from the anticoagulation regimen or the tumor)\r\n* Note: Subjects with a venous filter (e.g. vena cava filter) are not eligible for this studyXx_NEWLINE_xXCurrent use of anticoagulants (warfarin, heparin, direct thrombin inhibitors) at therapeutic levels.Xx_NEWLINE_xXIf patients require anticoagulation while on protocol, they should be switched from warfarin to another alternative anticoagulant such as low molecular weight heparin or oral direct factor Xa inhibitors as deemed appropriate by the treating physician for the duration they are on capecitabine (must be switched at least 1 week prior to starting capecitabine) to avoid drug-drug interaction of warfarin with capecitabineXx_NEWLINE_xXConcomitant anticoagulation at therapeutic doses with oral anticoagulants (eg, warfarin, direct thrombin and Factor Xa inhibitors) or platelet inhibitors (eg, clopidogrel);\r\n* Note: Low-dose aspirin for cardioprotection (per local applicable guidelines), low-dose warfarin (< 1 mg/day), and low dose, low molecular weight heparins (LMWH) are permitted; anticoagulation with therapeutic doses of LMWH is allowed in subjects without radiographic evidence of brain metastasis, who are on a stable dose of LMWH for at least 12 weeks before randomization, and who have had no complications from a thromboembolic event or the anticoagulation regimenXx_NEWLINE_xXSubjects must not be on full dose oral anticoagulation such as warfarin. Low dose warfarin and prophylactic as well as therapeutic low molecular weight heparin are allowable.Xx_NEWLINE_xXInternational normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.5 x ULN prior to study entry. Therapeutic anticoagulation with warfarin is allowed if target INR =< 3 on a stable dose of warfarin or on a stable dose of low molecular weight (LMW) heparin for > 2 weeks (14 days) at the time of enrollment.Xx_NEWLINE_xXFor patients requiring anti-coagulation with vitamin K antagonists, therapeutic level dosing of warfarin can be used with close monitoring of PT/INR by the site. Exposure may be decreased due to enzyme induction when on treatment, thus warfarin dosing may need to be adjusted based upon PT/INR. Consequently, when discontinuing dabrafenib, warfarin exposure may be increased and thus close monitoring via PT/INR and warfarin dose adjustments must be made as clinically appropriate. If clinically indicated, prophylactic low dose warfarin may be given to maintain central catheter patency.Xx_NEWLINE_xXHas prothrombin time (PT) or aPTT >1.5× upper limit of normal (ULN) or active uncontrolled coagulopathy or bleeding disorder. Participants therapeutically anticoagulated with warfarin, direct thrombin inhibitors, direct factor Xa inhibitors, or heparin are excluded from enrollment.Xx_NEWLINE_xXNeed for chronic anticoagulation therapy (chronic low dose aspirin is not an exclusion)Xx_NEWLINE_xXOR for subjects receiving warfarin or low molecular weight heparin (LMWH), the subjects must, in the Investigator's opinion, be clinically stable with no evidence of active bleeding while receiving anticoagulant therapy. The INR for these subjects may exceed 1.5 × ULN if that is the goal of anticoagulant therapy.Xx_NEWLINE_xXPatients requiring the use of warfarin are excludedXx_NEWLINE_xXConcomitant anticoagulation at therapeutic doses with oral anticoagulants (e.g., warfarin, direct thrombin and factor Xa inhibitors) or platelet inhibitors (e.g., clopidogrel)\r\n* Note: Low-dose aspirin for cardioprotection (per local applicable guidelines) and low dose low molecular weight heparin (LMWH) are permitted; anticoagulation with therapeutic doses of LMWH is allowed in subjects who are on a stable dose of LMWH for at least 6 weeks before first dose of study treatment, and who have had no clinically significant hemorrhagic complications from the anticoagulation regimen or the tumorXx_NEWLINE_xXAny evidence of bleeding diathesis (patients on therapeutic warfarin or heparin will be excluded)Xx_NEWLINE_xXSystemic anticoagulation with warfarin or other Vitamin K antagonists.Xx_NEWLINE_xXPatients receiving therapeutic anticoagulation (such as low-molecular-weight heparin or warfarin) should be on a stable doseXx_NEWLINE_xXConcomitant anticoagulation at therapeutic doses with oral anticoagulants (eg, warfarin, direct thrombin and Factor Xa inhibitors) or platelet inhibitors (eg, clopidogrel)\r\n* Note: low-dose aspirin for cardioprotection (per local applicable guidelines), low-dose warfarin (< 1 mg/day), and low dose, low molecular weight heparins (LMWH) are permitted if started > 6 months prior to randomization; LMWH used as therapeutic anticoagulation may increase observed PTT levels in subjects; anticoagulation with therapeutic doses of LMWH is allowed in subjects without radiographic evidence of brain metastasis, who are on a stable dose of LMWH for at least 24 weeks before randomization, and who have had no complications from a thromboembolic event or the anticoagulation regimenXx_NEWLINE_xXConcomitant use of warfarin or other vitamin K antagonistsXx_NEWLINE_xXDeep venous thrombosis within 6 months prior to study treatment, unless the patient is anti-coagulated without the use of warfarin for ?2 weeks prior to study treatment; in this situation, low molecular weight heparin is preferredXx_NEWLINE_xXHistory of thromboembolic event or other condition currently requiring anticoagulation with warfarin (coumadin); patients who are treated with low molecular weight heparin or fondaparinux are eligibleXx_NEWLINE_xXParticipants receiving oral warfarin are not eligible for this study (unless warfarin is discontinued at least 7 days prior to commencement of treatment and for the duration of the study, or oral warfarin is converted to LMWH, where local clinical opinion considers this an acceptable option).Xx_NEWLINE_xXConcurrent use of warfarinXx_NEWLINE_xXSubject is currently receiving warfarin or other coumarin-derived anticoagulant for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH), or fondaparinux is allowed.Xx_NEWLINE_xXPatients may not receive Coumadin while on study; patients may receive low molecular weight heparin or novel oral anticoagulants (eg. dabigatran, apixaban, rivaroxaban) provided that the dose is held 1-2 days before injections are given and biopsies are performed per the protocol; anti-platelet agents and herbal substances are allowed at the discretion of the treating endoscopistXx_NEWLINE_xXRequirement for anti-coagulation with Coumadin, low molecular weight heparin and anti-thrombin inhibitors will be accepted if anticoagulation has been stable for at least 4 weeks and no recent history of prior bleeding complicationsXx_NEWLINE_xXPatients receiving therapeutic doses of warfarinXx_NEWLINE_xXPatient is currently receiving warfarin or other coumadin-derived anticoagulant for treatment, prophylaxis or otherwise; therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowedXx_NEWLINE_xXConcomitant use of warfarin or other vitamin K antagonistsXx_NEWLINE_xXCoagulopathy, including the use of Coumadin or heparin anticoagulants that cannot be discontinued for the cryoablation procedure; NOTE: heparin for line patency without detectable lab abnormalities for coagulation will be allowedXx_NEWLINE_xXReceiving warfarin (or other coumarin derivatives) and is unable to switch to low molecular weight heparin (LMWH) before the first dose of study drugXx_NEWLINE_xXAnticoagulation is allowed if target INR =< 1.5 on a stable dose of warfarin or on a stable dose of anticoagulant for > 2 weeks at time of randomization; for patients on therapeutic anti-coagulants, medication must be clinically held peri-procedure (bone marrow aspirate) per standard clinical managementXx_NEWLINE_xXWithin 14 days prior to the first study treatment (cycle 1, day 1): International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN\r\n* This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation (such as low-molecular-weight heparin or warfarin) should be on a stable doseXx_NEWLINE_xXInternational normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN\r\n* This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation (such as low-molecular-weight heparin or warfarin) should be on a stable doseXx_NEWLINE_xXCurrent use of warfarin or other vitamin K antagonistsXx_NEWLINE_xXReceiving any of the following medications:\r\n* Therapeutic doses of any anticoagulant, including low-molecular weight heparin (LMWH); concomitant use of warfarin, even at prophylactic doses, is prohibited\r\n* Digoxin, digitoxin, lanatoside C, or any type of digitalis alkaloids\r\n* Colony-stimulating factors (CSFs) that cannot be held during the monitoring period for dose-limiting toxicities (DLT)Xx_NEWLINE_xXThe subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or Factor Xa inhibitors, or antiplatelet agents (e.g., clopidogrel); low dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are permittedXx_NEWLINE_xXPatients requiring concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or factor Xa inhibitors, antiplatelet agents (e.g. clopidogrel) or new oral anticoagulants; low-dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are permittedXx_NEWLINE_xXActivated partial thromboplastin time (aPTT) =< 1.5 x ULN (unless on prophylactic or therapeutic dosing with low molecular weight heparin) (obtained within 28 days prior to first study treatment)Xx_NEWLINE_xXPatients may not have evidence of coagulopathy or bleeding diathesis; therapeutic anticoagulation for prior thromboembolic events is permitted; the clinical indication for therapeutic anticoagulation must be clearly documented prior to enrollment and must be discussed with the P.I.; patients who are on greater than or equal to 2 anti-thrombotic agents, including but not limited to anti-platelet agents (non-steroidal anti-inflammatory drugs [NSAIDs]/aspirin, clopidogrel), heparin, low molecular weight heparin (LMWH), warfarin, and a direct thrombin inhibitor, will be excludedXx_NEWLINE_xXInternational normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.5 x ULN within 14 days prior to study entry; therapeutic anticoagulation with warfarin is allowed if target INR =< 3 on a stable dose of warfarin or on a stable dose of low molecular weight (LMW) heparin for > 2 weeks (14 days) at the time of enrollmentXx_NEWLINE_xXInternational normalized ratio (INR) and activated partial thromboplastin time (aPTT) ? 1.5 X ULN; this applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation (such as low-molecular-weight heparin or warfarin) should be on a stable doseXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5\r\n* Use of rivaroxaban, apixaban, edoxaban or warfarin is an exclusion criteria; therapy with heparin, low molecular weight heparin (LMWH), dabigatran or fondaparinux is allowedXx_NEWLINE_xXCurrently receiving rivaroxaban, apixaban, endoxaban, warfarin or other warfarin derived anticoagulant; therapy with heparin, low molecular weight heparin (LMWH), dabigatran or fondaparinux is allowed; if transitioning from a prohibited anticoagulant, a minimum washout of 7 days from last dose of the prohibited medication is required prior to ribociclib startXx_NEWLINE_xXRequirement of anticoagulant therapy with oral vitamin K antagonists such as Coumadin (warfarin); low-dose anticoagulants for the maintenance of patency in a central venous access device or the prevention of deep vein thrombosis or pulmonary embolism is allowed; therapeutic use of low molecular weight heparin is allowedXx_NEWLINE_xXConcomitant use of warfarin or other Vitamin K antagonistsXx_NEWLINE_xXAble to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to aspirin [ASA] may use low molecular weight heparin or equivalent)Xx_NEWLINE_xXRequires the use of warfarin (because of potential drug-drug interactions that may potentially increase the exposure of warfarin)Xx_NEWLINE_xXRequires concomitant therapeutic anticoagulation (i.e., warfarin) for reasons other than venous catheter patencyXx_NEWLINE_xXRequire therapeutic use of anticoagulants other than daily aspirin or low molecular weight heparinXx_NEWLINE_xXRequires therapeutic anticoagulation with warfarin or other vitamin K antagonistsXx_NEWLINE_xXPatients on warfarinXx_NEWLINE_xXOn warfarin therapy or other vitamin K antagonists within 7 days of treatment initiationXx_NEWLINE_xXRequires or is currently receiving anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon) within 28 days of first dose of study drugXx_NEWLINE_xXBleeding or thrombotic disorders or use of anticoagulants, such as warfarin, or similar agents requiring therapeutic international normalized ration (INR) monitoring; (treatment with low molecular weight heparin [LMWH] is allowed)Xx_NEWLINE_xXOngoing risk for bleeding due to active peptic ulcer disease or bleeding diathesis or requirement for systemic anticoagulation with unfractionated heparin, low-molecular-weight heparin or heparin fractions (eg, enoxaparin, dalteparin, fondaparinux) or oral anticoagulants (eg, apixaban, rivaroxaban, dabigatran etexilate, warfarin). Note: Use of heparin or thrombolytic agents for local maintenance or clearance of a central venous catheter is permitted.Xx_NEWLINE_xXRequires anticoagulation with warfarin or equivalent vitamin K antagonistsXx_NEWLINE_xXSubjects receiving any vitamin K antagonists (VKAs) prior to randomization or receiving more than 36 hours treatment with LMW(low molecular weight Heparin) in therapeutic doses prior to randomization;Xx_NEWLINE_xXAble to take aspirin 81 mg orally daily or if intolerant of aspirin, able to take a substitute thromboprophylaxis such as low molecular weight heparinXx_NEWLINE_xXTherapeutic anticoagulation with drugs requiring INR monitoring (except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous device) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid < 325mg per day)Xx_NEWLINE_xXRequirement for anticoagulation treatment that increases INR or aPTT above the normal range (low molecular weight heparin and heparin line flush allowed).Xx_NEWLINE_xXParticipants must agree to ongoing anticoagulation as prophylaxis against deep vein thrombosis (DVT) using aspirin (81 or 325 mg) daily, warfarin or low molecular weight heparin, or a patient already taking another oral anticoagulant (e.g. direct thrombin inhibitors for atrial fibrillation) may continue that agentXx_NEWLINE_xXInternational normalized ratio (INR) > 2 and/or partial thromboplastin time (PTT) > 80\r\n* Patients who are on anticoagulation medication that may not be safely held for the procedure (>= 5 days for antiplatelet agents and warfarin; >= 24 hours for low-molecular weight heparin formulations) will be excludedXx_NEWLINE_xXRequires anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon)Xx_NEWLINE_xXAnticoagulation is permitted but patients may not be on warfarinXx_NEWLINE_xXAnticoagulation therapy (within 7 days of Study Day 1), except low molecular weight heparins or low dose aspirin.Xx_NEWLINE_xXPatients with history of bleeding diathesis, arterial thromboembolism, current use of therapeutic anticoagulation with oral vitamin K antagonists, factor Xa inhibitors, heparin products, oral direct thrombin inhibitors, or presence of non-healing wounds; low-dose anticoagulants for maintenance of patency of central venous access device or prevention of deep venous thrombosis is allowedXx_NEWLINE_xXConcurrent use of warfarinXx_NEWLINE_xXPatients must not be on therapeutic anti-coagulation; prophylactic anticoagulation (i.e. low dose warfarin) of venous or arterial devices is allowed provided that the requirements for PT, INR, and PTT are metXx_NEWLINE_xXConcomitant use of warfarin or other vitamin K antagonistsXx_NEWLINE_xXRequires anticoagulation with warfarin or equivalent vitamin K antagonists (eg, phenprocoumon)Xx_NEWLINE_xXThe patient is receiving therapeutic anticoagulation with warfarin, low molecular weight heparin, or similar agents; patients receiving prophylactic, low-dose anticoagulation therapy are eligible provided that the coagulation parameters defined in the inclusion criteria (INR =< 1.5 or PT =< 1.5 x ULN and PTT/aPTT =< 1.5 x ULN)Xx_NEWLINE_xXCurrent use of therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulants; heparin and/or low molecular weight heparins or other anticoagulants are allowedXx_NEWLINE_xXReceiving therapeutic anticoagulation (Coumadin or low molecular weight heparin, heparin, apixaban, dabigatran, rivaroxaban, warfarin)Xx_NEWLINE_xXWarfarin is not permitted; prophylactic or therapeutic use of low molecular-weight heparin (e.g., enoxaparin) or direct thrombin inhibitors are permittedXx_NEWLINE_xXPatients on full-dose anticoagulants (e.g., warfarin or low molecular weight [LMW] heparin) must meet both of the following criteria:\r\n* No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)\r\n* In-range INR (between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparinXx_NEWLINE_xXAble to take aspirin 81 mg daily or if intolerant of aspirin, able to take a substitute thromboprophylaxis such as low molecular weight heparin at a thromboprophylactic dose (such as enoxaparin 0.5 mg/kg once daily)Xx_NEWLINE_xXCurrent use of therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulants; heparin and/or low molecular weight heparins are allowedXx_NEWLINE_xXUnable to tolerate thromboembolic prophylaxis including, as clinically indicated, aspirin, Coumadin (warfarin) or dose adjusted low-molecular weight heparinXx_NEWLINE_xXConcomitant use of warfarin or other vitamin K antagonistsXx_NEWLINE_xXRequirement for anticoagulation treatment that increases INR or aPTT above the normal range (low dose DVT or line prophylaxis is allowed).Xx_NEWLINE_xXAble to take aspirin (81 mg) daily or alternative therapy as prophylactic anticoagulationXx_NEWLINE_xXRequires anticoagulation with warfarin or equivalent vitamin K antagonistsXx_NEWLINE_xXConcomitant use of warfarin or other vitamin K antagonistsXx_NEWLINE_xXPatient is currently receiving warfarin or other coumarin-derived anticoagulant for treatment, prophylaxis or otherwise; therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowedXx_NEWLINE_xXInternational normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN; this applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation (such as low-molecular-weight heparin or warfarin) should be on a stable doseXx_NEWLINE_xXTherapeutic anticoagulation, including but not limited to: low-molecular weight heparin (LMWH), heparin, or warfarin; anticoagulants must be discontinued 10 days prior to the first administration of bevacizumab; prophylactic use of anticoagulants is allowedXx_NEWLINE_xXAbnormality in coagulation parameters. Received oral or parenteral anticoagulants or thrombolytic agents within 10 days of the first dose of trial drug. Low dose high molecular weight heparin is permitted if international normalized ratio is within the normal rangeXx_NEWLINE_xXThe subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or factor Xa inhibitors, or antiplatelet agents (e.g., clopidogrel); low dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are permittedXx_NEWLINE_xXWithin 3 months of registration: Activated partial thromboplastin time (aPTT) =< 1.5 x ULN (unless on prophylactic or therapeutic dosing with low molecular weight heparin)Xx_NEWLINE_xXWilling and able to take aspirin (81 mg) daily as prophylactic anticoagulation (patients intolerant to acetylsalicylic acid [ASA] may use warfarin or low molecular weight heparin)Xx_NEWLINE_xXThey must not require concomitant treatment with warfarin.Xx_NEWLINE_xXPatients must not be on any dose of warfarin or are on full dose anticoagulation with other agents, including low molecular weight heparin, antithrombin agents, anti-platelet agents and full dose aspirin within 7 days prior to first dose of study drug; patients on prophylactic doses of low-molecular weight heparin are allowedXx_NEWLINE_xXSubject is receiving therapeutic anticoagulation therapy; low dose anti-coagulation (e.g., low dose heparin or warfarin) for catheter prophylaxis will be permitted; use of aspirin for treatment of atrial fibrillation will also be permittedXx_NEWLINE_xXConcomitant treatment with therapeutic anticoagulants such as warfarinXx_NEWLINE_xXRequires anticoagulation with warfarin or equivalent vitamin K antagonistXx_NEWLINE_xXConcomitant use of warfarin or other vitamin K antagonistsXx_NEWLINE_xXPatients who are currently receiving therapeutic anticoagulants (including aspirin, low molecular weight heparin, and others) are not eligibleXx_NEWLINE_xXPatients on Coumadin must be changed to Lovenox at least 1 week prior to starting capecitabine; low dose (1 mg) Coumadin is allowed; intravenous and low-molecular weight heparin are permittedXx_NEWLINE_xXAnticoagulants/anti-platelets: patients on therapeutic (treatment) dose of anticoagulants (e.g. warfarin, low molecular-weight heparin) are not eligible; patients are not allowed to take aspirin, clopidogrel, ticlopidine, Aggrenox; patients on prophylactic anticoagulation may be enrolled and treated on study as long as their platelet count is monitored closely and maintained at > 75,000 while they are receiving dasatinibXx_NEWLINE_xXAble to take aspirin (81 or 325 mg) daily for prophylactic anticoagulation (patients intolerant to acetylsalicylic acid, ASA, may use warfarin or low molecular weight heparin or other anticoagulants deemed appropriate by the principal investigator [PI])Xx_NEWLINE_xXAnticoagulation with warfarinXx_NEWLINE_xXConcomitant use of warfarin or other vitamin K antagonistsXx_NEWLINE_xXProthrombin (PT) and activated partial thromboplastin time (aPTT) =< 1.2 x upper limit of normal (ULN) prior to biopsy; patients with prior history of thrombosis/embolism are allowed to be on anticoagulation, understanding that anticoagulation will be held in the perioperative period per the neurosurgical team’s recommendations; low molecular weight heparin (LMWH) is preferred; if a patient is on warfarin, the international normalized ratio (INR) is to be obtained and value should be below 2.0 prior to biopsyXx_NEWLINE_xXThe subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or Factor Xa inhibitors, or antiplatelet agents (eg, clopidogrel); low dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are permittedXx_NEWLINE_xXReceiving therapeutic anticoagulation (except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous device) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid < 325 mg once daily [QD])Xx_NEWLINE_xXInternational normalized ratio (INR) > 2.5 and/or partial thromboplastin time (PTT) > 80 \r\n* Patients who are on anticoagulation medication that may not be safely held for the procedure (>= 5 days for antiplatelet agents and warfarin; >= 24 hours for low-molecular weight heparin formulations) will be excludedXx_NEWLINE_xXUse of antiplatelet agents other than low-dose aspirinXx_NEWLINE_xXPatients who are currently taking therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulantXx_NEWLINE_xXCurrent use of anticoagulants (warfarin, heparin, direct thrombin inhibitors) at therapeutic levelsXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5; (anticoagulation is allowed if target INR =< 1.5 on a stable dose of warfarin or on a stable dose of low molecular weight [LMW] heparin for > 2 weeks at the first dose of study agent)Xx_NEWLINE_xXInternational normalized ratio (INR): =< 1.5 (patients on warfarin need to be converted to low-molecular-weight heparin [LMWH] during study participation to be eligible)Xx_NEWLINE_xXRequires anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon)Xx_NEWLINE_xXPatients taking Coumadin, other agents containing warfarin, rivaroxaban, or dabigatran; (exception: low dose Coumadin [1 mg or less daily] administered prophylactically for maintenance of in-dwelling lines or ports is allowed)Xx_NEWLINE_xXPatients who are receiving any anti-coagulation or anti-platelet therapy including, but not limited to, Clopidogrel, vitamin K antagonists (e.g. warfarin) , heparin, low molecular weight heparin, dabigatran, rivaroxaban, and apixabanXx_NEWLINE_xXThe subject is receiving concomitant treatment with warfarin, warfarin-related agents, or low molecular weight heparin (LMWH) at the time of study entry at therapeutic doses; low-dose warfarin (=< 1 mg/day) or LMWH at prophylactic doses are permittedXx_NEWLINE_xXPatients who are currently taking therapeutic doses of warfarin sodium or any other Coumadin-derivative anticoagulantXx_NEWLINE_xXTherapeutic level dosing of warfarin can be used with close monitoring of PT/INR by the site; exposure may be decreased due to enzyme induction when on treatment, thus warfarin dosing may need to be adjusted based upon PT/INR; consequently, when discontinuing dabrafenib, warfarin exposure may be increased and thus close monitoring via PT/INR and warfarin dose adjustments must be made as clinically appropriate; prophylactic low dose warfarin may be given to maintain central catheter patencyXx_NEWLINE_xXRequirement for anticoagulation with warfarinXx_NEWLINE_xXConcurrent or recent (within 1 month) use of thrombolytic agents, or full-dose anticoagulants (except to maintain patency of preexisting, permanent indwelling IV catheters). Of note, therapy with low-molecular weight heparin is acceptable as long as the INR < 2.0.Xx_NEWLINE_xXThe subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or factor Xa inhibitors, or antiplatelet agents (e.g. clopidogrel); low dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are permittedXx_NEWLINE_xXFor patients with bulky disease (tumors > 5 cm); must be able to take aspirin (81 mg or 325 mg) daily as prophylactic anticoagulation (patients intolerant to acetylsalicylic acid [ASA] may use warfarin or low molecular weight heparin)Xx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program; able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin)Xx_NEWLINE_xXPatients requiring use of warfarin for therapeutic purposes; subcutaneous heparin or fractionated heparin products are permitted if the goal is not to achieve full-dose systemic anticoagulationXx_NEWLINE_xXPatients being treated with full dose warfarin are excluded. Patients with history of deep vein thrombosis or pulmonary embolus who are being treated with therapeutic doses of low molecular weight heparin or prophylactic dose anticoagulants may be enrolled.Xx_NEWLINE_xXPatients on full-dose anticoagulants (e.g., warfarin or low molecular weight [LMW] heparin) must meet both of the following criteria:\r\n* No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)\r\n* In-range international normalized ratio (INR) (maximum [max] =< 3) on a stable dose of oral anticoagulant for greater than 1 month or on a stable dose of low molecular weight heparinXx_NEWLINE_xXRelapsed/refractory MCL: Requires anticoagulation with warfarin or equivalent vitamin K antagonistXx_NEWLINE_xXNewly diagnosed MCL: Requires concomitant anticoagulation with warfarin or equivalent vitamin K antagonistXx_NEWLINE_xXCurrently receiving anticoagulation with therapeutic doses of warfarin (low-molecular weight heparin is permitted)Xx_NEWLINE_xXPatients unable to discontinue anti-platelet or anti-coagulant medicine such as clopidogrel, dabigatran, warfarin, or low molecular weight heparin; use of aspirin is not an exclusion criteriaXx_NEWLINE_xXProthrombin time/international normalized ratio (PT/INR) < 1.4 for patients not on warfarin confirmed by testing within 14 days prior to registration; patients on full-dose anticoagulants (e.g., warfarin or low molecular weight [LMW] heparin) must meet both of the following criteria:\r\n* No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)\r\n* In-range INR (between 2.5 and 3.5) on a stable dose of warfarin-based oral anticoagulant; or on a stable dose of low molecular weight heparin; or INR between 1.5 and 2 if a Greenfield filter is in placeXx_NEWLINE_xXAble to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (subjects intolerant to aspirin may use warfarin or low molecular weight heparin) if clinically indicatedXx_NEWLINE_xXContraindication to any of the required concomitant drugs, including proton pump inhibitor (e.g. lansoprazole), enteric coated aspirin or if a history of prior thrombotic disease, warfarin or low molecular weight heparinXx_NEWLINE_xXPatients requiring warfarin therapy are excluded, low molecular weight heparin is permittedXx_NEWLINE_xXPatients on therapeutic anticoagulation; Note: prophylactic anticoagulation (i.e. intraluminal heparin) for venous or arterial access devices is allowedXx_NEWLINE_xXAble to take aspirin 81 mg daily or if intolerant of aspirin, able to take a substitute thromboprophylaxis such as low molecular weight heparin at a thromboprophylactic dose (such as enoxaparin 0.5 mg/kg once daily)Xx_NEWLINE_xXAble to take aspirin (81 and 325 mg) daily as prophylactic anticoagulation (patients intolerant to aspirin [ASA] may use warfarin or low molecular weight heparin)Xx_NEWLINE_xXPartial thromboplastin time =< institutional upper limit of normal, unless receiving therapeutic low molecular weight heparinXx_NEWLINE_xXCurrent use of warfarin sodium or any other coumadin-derivative anticoagulant; participant must be off coumadin-derivative anticoagulants for at least 7 days prior to planned start of study treatment; low molecular weight heparin and factor Xa inhibitors are allowedXx_NEWLINE_xXPatients with a history of hypersensitivity to heparin or the presence of heparin-induced thrombocytopenia.Xx_NEWLINE_xXNeed for ongoing therapeutic anticoagulationXx_NEWLINE_xXPatients who require warfarin or other vitamin K antagonists for anticoagulation (other anticoagulants are allowed after consultation with the principal investigator)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5; (anticoagulation is allowed if target INR =< 1.5 on a stable dose of warfarin or on a stable dose of low molecular weight [LMW] heparin for > 2 weeks at time of randomization)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 and partial thromboplastin time (PTT) =< 1.5 x ULN for patients who are not being treated with therapeutic anticoagulation; therapeutic or prophylactic anticoagulation is allowed if a patient has been on a stable dose of low molecular weight (LMW) heparin for > 2 weeks at the time of randomization; subjects on therapeutic or prophylactic anticoagulation including warfarin will have PTT and INR as determined by the Investigator; prophylactic use of an anticoagulant to maintain patency of a vascular access device is also allowed)Xx_NEWLINE_xXNo warfarin therapy; low molecular weight heparin anticoagulation is permitted provided that patients have been clinically stable on anti-coagulation for at least 2 weeks prior to day 1 of study drug and meet platelet inclusion criteria; no history of active gastrointestinal (GI) bleeding or other major bleeding within previous 6 months prior to day 1 of study drugXx_NEWLINE_xXCurrently receiving anticoagulation therapy with warfarin;Xx_NEWLINE_xXRequires anticoagulation that cannot be discontinued prior to biopsy\r\n* Note: Exception if able to hold antiplatelet agents 7 days prior to the injections and biopsy\r\n* NOTE: Low molecular weight heparin (LMWH) will be allowed for bridging if on warfarin\r\n* NOTE: Heparin for line patency without detectable lab abnormalities for coagulation will be allowedXx_NEWLINE_xXSubject is able to take prophylactic anticoagulation as detailed in section 9.1 (patients intolerant to aspirin may use warfarin or low molecular weight heparin).Xx_NEWLINE_xXTreatment with unfractionated heparin; patients taking an anticoagulant must use warfarin or a low molecular weight heparinXx_NEWLINE_xXPatients who are currently taking therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulantXx_NEWLINE_xXPatient receiving active treatment of anticoagulants (i.e. warfarin, low molecular weight heparins)Xx_NEWLINE_xXRequires anticoagulation with warfarin or equivalent vitamin K antagonistsXx_NEWLINE_xXInternational normalized ratio (INR) and activated partial thromboplastin time (aPTT) ? 1.5 × ULN (this applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation, such as low-molecular-weight heparin or warfarin, should be on a stable dose)Xx_NEWLINE_xXORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Chronic anticoagulation, not including aspirin, but including heparins, warfarin, oral anticoagulation or other platelet function inhibitorsXx_NEWLINE_xXHPV-ASSOCIATED OROPHARYNX SQUAMOUS CELL CARCINOMA: Chronic anticoagulation, not including aspirin, but including heparins, warfarin, oral anticoagulation or other platelet function inhibitorsXx_NEWLINE_xXIf they are on any dose of warfarin or are on full dose anticoagulation with other agents, including low molecular weight heparin, antithrombin agents, anti-platelet agents and full dose aspirin within 7 days prior to first dose of study drug; patients on prophylactic doses of low-molecular weight heparin are allowedXx_NEWLINE_xXNeed for anticoagulation with a vitamin K antagonist (warfarin); other anticoagulants and\r\nantiplatelet agents are allowedXx_NEWLINE_xXInternational normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN (This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation [such as low-molecular-weight heparin or warfarin] should be on a stable dose.)Xx_NEWLINE_xXPatients on therapeutic anticoagulationXx_NEWLINE_xXPatients requiring therapeutic anticoagulation with drugs requiring INR monitoring or anti-platelet therapy, except for acetylsalicylic acid (aspirin) ? 325 mg per day, are not eligibleXx_NEWLINE_xXRequires continued use of warfarin for anticoagulation and cannot stop warfarin or be safely switched to another anticoagulantXx_NEWLINE_xXConcomitant anticoagulation at therapeutic doses with oral anticoagulants (eg, warfarin, direct thrombin and factor Xa inhibitors) or platelet inhibitors (eg, clopidogrel)\r\n* Note: Low-dose aspirin for cardioprotection (per local applicable guidelines), low-dose warfarin (< 1 mg/day), and low dose, low molecular weight heparins (LMWH) are permitted; anticoagulation with therapeutic doses of LMWH is allowed in subjects who are on a stable dose of LMWH for at least 6 weeks before first dose of study treatment, and who have had no clinically significant hemorrhagic complications from the anticoagulation regimen or the tumorXx_NEWLINE_xXPatients requiring therapeutic anticoagulation and irreversible platelet inhibitors (e.g. clopidogrel, prasugrel, or ticagrelor). Low dose aspirin for cardiac prophylaxis is allowed.Xx_NEWLINE_xXConcomitant use of warfarin or other vitamin K antagonistsXx_NEWLINE_xXRequires concomitant anticoagulation with warfarin or equivalent vitamin K antagonist.Xx_NEWLINE_xXPatient is currently receiving warfarin or other Coumarin-derived anticoagulant for treatment, prophylaxis, or other reasons. Therapy with heparin, low molecular weight heparin, or fondaparinux is allowed.Xx_NEWLINE_xXCurrent or recent (within 10 days prior to first dose of bevacizumab) use of aspirin (> 325 mg/day); prophylactic and therapeutic use of anticoagulants is allowed, e.g., warfarin (1 mg once daily [QD]) for catheter prophylaxis and prophylactic low molecular weight heparin (i.e., enoxaparin [40 mg QD])Xx_NEWLINE_xXPatient is currently receiving warfarin or other coumarin derived anti-coagulant, for treatment, prophylaxis or otherwise; therapy with heparin, low molecular weight heparin (LMWH), or fondaparinux is allowedXx_NEWLINE_xXTherapeutic anticoagulation is allowed for patients on a stable dose of warfarin or low molecular weight heparinXx_NEWLINE_xXCurrent use of anticoagulation; NOTE: use of low-dose anticoagulation medications (such as heparin) that are used to maintain the patency of a central intravenous catheter is allowedXx_NEWLINE_xXInternational normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN\r\n* This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation (such as low-molecular-weight heparin or warfarin) should be on a stable doseXx_NEWLINE_xXTherapeutic-dose anticoagulation (e.g., warfarin, low-molecular weight heparin [LMWH], or novel oral anticoagulants) must be discontinued and coagulation parameters must be normalized prior to the first dose of abiraterone/enzalutimide. Prophylactic anticoagulation, with low doses (per standard practice) of agents such as low molecular weight heparin (LMWH), direct thrombin inhibitors, or factor Xa inhibitors is permitted.Xx_NEWLINE_xXPatients may not be on warfarin, factor Xa inhibitors and direct thrombin inhibitors; Note: low molecular weight heparin and prophylactic low dose warfarin are permitted; APTT/PTT must meet the inclusion criteria; subjects taking warfarin must have their international normalized ratio (INR) followed closelyXx_NEWLINE_xXWithin 14 days prior to registration: Partial thromboplastin time (PTT) =< institution’s ULN, unless receiving therapeutic low molecular weight heparinXx_NEWLINE_xXCurrent use of warfarin sodium or any other coumadin-derivative anticoagulant; participants must be off coumadin-derivative anticoagulants for at least 7 days prior to starting study drug; low molecular weight heparin is allowedXx_NEWLINE_xXMust be able to take acetylsalicylic acid (ASA) daily as prophylactic anticoagulation; patients intolerant to ASA may use low molecular weight heparin or equivalent; warfarin will be allowed provided patient is full anticoagulated, with an international normalized ratio (INR) of 2-3Xx_NEWLINE_xXTherapeutic anticoagulation with warfarin, antiplatelet agents (e.g., clopidogrel), thrombin, or Factor Xa inhibitors is not allowed; therapeutic anticoagulation with low molecular weight heparin (LMWH) is allowed as well as prophylactic anticoagulation using low dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day), and LMWHXx_NEWLINE_xXCurrent use of warfarin, factor Xa inhibitors and direct thrombin inhibitors; Note: low molecular weight heparin and prophylactic low dose warfarin are permitted; PT/PTT must meet the inclusion criteria; subjects taking warfarin must have their INR followed closelyXx_NEWLINE_xXPatients may not be on coumarin anti-coagulants (warfarin, etc.); heparin, low-molecular weight heparin (LMWH), or other antithrombotic medications are permittedXx_NEWLINE_xXPatients requiring therapeutic anticoagulationXx_NEWLINE_xXIndividuals who require therapy with warfarinXx_NEWLINE_xXReceiving therapeutic anticoagulation (Coumadin or low molecular weight heparin)Xx_NEWLINE_xXTUMOR BIOPSY SEQUENCING: Patients who require use of coumarin-derivative anticoagulants such as warfarin are excluded; low molecular weight heparin is permitted for prophylactic or therapeutic useXx_NEWLINE_xXTREATMENT: Patients who require use of coumarin-derivative anticoagulants such as warfarin are excluded; low molecular weight heparin is permitted for prophylactic or therapeutic useXx_NEWLINE_xXPatients receiving anticoagulation or anti-platelet therapy are excluded due to the risk of thrombocytopenia with navitoclax\r\n* Excluded agents include heparin or low molecular weight heparin, warfarin, clopidogrel, ibuprofen and other non-steroidal anti-inflammatory drugs (NSAIDS), tirofiban, and other anticoagulants, drugs, or herbal supplements that affect platelet function\r\n* Administration of heparin to keep subject's infusion lines patent is allowed; low-dose anticoagulation medications that are used to maintain the patency of a central intravenous catheter are allowed\r\n* Aspirin will not be allowed within 7 days prior to the first dose of navitoclax or during navitoclax administration; however, subjects who have previously received aspirin therapy for thrombosis prevention, may resume a low dose (i.e., maximum 100 mg once daily [QD]) of aspirin if platelet counts are stable (>= 50,000/mm3) through 6 weeks of navitoclax administration \r\n* All decisions regarding treatment with aspirin therapy will be determined by the investigator in conjunction with the medical monitorXx_NEWLINE_xXPatients on therapeutic anticoagulation Note: prophylactic anticoagulation (i.e. intraluminal heparin) for venous or arterial access devices is allowedXx_NEWLINE_xXTherapeutic level dosing of warfarin can be used with close monitoring of PT/INR by the site; exposure may be decreased due to enzyme induction when on treatment, thus warfarin dosing may need to be adjusted based upon PT/INR; consequently, when discontinuing dabrafenib, warfarin exposure may be increased and thus close monitoring via PT/INR and warfarin dose adjustments must be made as clinically appropriate; prophylactic low dose warfarin may be given to maintain central catheter patencyXx_NEWLINE_xXAble to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to acetylsalicylic acid [ASA] may use warfarin or heparin)Xx_NEWLINE_xXThe subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or coumadin-related agents, thrombin or factor Xa (FXa) inhibitors, and antiplatelet agents (eg, clopidogrel); low dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are permitted; therapeutic anticoagulation with LMWHs may be allowed in certain circumstances as outlinedXx_NEWLINE_xXConcomitant use of warfarin or other vitamin K antagonists within the last 28 daysXx_NEWLINE_xXPatients receiving warfarin anticoagulation, who cannot be transitioned to other agents such as enoxaparin or dabigatran, and for whom anticoagulants cannot be held for up to 24 hoursXx_NEWLINE_xXSubjects on warfarin. Prophylactic anticoagulation with low molecular weight heparin\n             is allowedXx_NEWLINE_xXPatients must not be on any anticoagulationXx_NEWLINE_xXPatient is currently receiving warfarin or other coumarin derived anti-coagulant, for treatment, prophylaxis or otherwise; therapy with heparin, low molecular weight heparin (LMWH), or fondaparinux is allowedXx_NEWLINE_xXPatient is currently receiving warfarin or other coumarin-derived anticoagulant for treatment, prophylaxis or otherwise; therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowedXx_NEWLINE_xXInternational normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN\r\n* This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation (such as low?molecular weight heparin or warfarin) should be on a stable doseXx_NEWLINE_xXPatient is currently receiving warfarin or other coumarin-derived anticoagulant for treatment, prophylaxis or otherwise; therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowedXx_NEWLINE_xXSubject is currently receiving warfarin or other coumarin-derived anti-coagulant for treatment, prophylaxis or otherwise; therapy with heparin, low molecular weight heparin (LMWH), or fondaparinux is allowedXx_NEWLINE_xXPatients who are currently receiving therapeutic anti-coagulation with heparin, low-molecular weight heparin or Coumadin are not eligible for this trialXx_NEWLINE_xXPatient is currently receiving warfarin or other coumarin derived anti-coagulant, for treatment, prophylaxis or otherwise; therapy with heparin, low molecular weight heparin (LMWH), or fondaparinux is allowedXx_NEWLINE_xXConcurrent use of anti-coagulants (warfarin, etc.) other than low-molecular weight heparin (LMWH); medication must be stopped before time of registration; if patient has recently been on anti-coagulants other than LMWH, patient must have international normalized ratio (INR) =< 2Xx_NEWLINE_xXPatients who require use of coumarin-derivative anticoagulants such as warfarin are excluded; low molecular weight heparin is permitted for prophylactic or therapeutic use; low-dose warfarin (=< 1 mg/day) is permittedXx_NEWLINE_xXTherapeutic level dosing of warfarin can be used with close monitoring of PT/INR by the site; exposure may be decreased due to enzyme induction when on treatment, thus warfarin dosing may need to be adjusted based upon PT/INR; consequently, when discontinuing dabrafenib, warfarin exposure may be increased and thus close monitoring via PT/INR and warfarin dose adjustments must be made as clinically appropriate; prophylactic low dose warfarin may be given to maintain central catheter patencyXx_NEWLINE_xXAble to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to acetylsalicylic acid [ASA] may use warfarin or low molecular weight heparin)Xx_NEWLINE_xXPatients requiring chronic anticoagulation with warfarin are excluded; patients treated with low molecular weight heparin or unfractionated heparin are eligible if on a stable dose without evidence of clinically significant bleeding for at least 2 weeks prior to enrollmentXx_NEWLINE_xXCurrent treatment or treatment within 7 days of screening with a vitamin K\n             antagonist, such as warfarin. Patients who require anticoagulation due to their\n             central line may receive an alternative agent, such as low molecular weight heparin\n             (LMWH).Xx_NEWLINE_xXActivated partial thromboplastin time (APTT) < 1.2 times upper limit of normal (ULN); (Note: use of warfarin is prohibited; low molecular weight heparin is allowed, so long as these criteria are met)Xx_NEWLINE_xXInternational normalized ratio (INR) < 1.2 times ULN; (Note: use of warfarin is prohibited; low molecular weight heparin is allowed, so long as these criteria are met)Xx_NEWLINE_xXAny of the following conditions: \r\n* Serious or non-healing wound, ulcer, or bone fracture\r\n* Current use of therapeutic warfarin; Note: low molecular weight heparin is allowed; prothrombin time (PT)/partial thromboplastin time (PTT) must meet the inclusion criteria\r\n* History of bleeding disorder, including patients afflicted with hemophilia, disseminated intravascular coagulation, or any other abnormality of coagulation potentially predisposing patients to bleeding\r\n* History of hemoptysis in excess of 2.5 mL (1/2 teaspoon ) within 8 weeks prior to first dose of study drug\r\n* Poorly controlled depression or anxiety disorder, or recent (=< 6 months) suicidal ideation\r\n* HIV-positive patients on combination antiretroviral therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicatedXx_NEWLINE_xXPatients who are currently taking therapeutic doses of warfarin sodium or any other Coumadin-derivative anticoagulantXx_NEWLINE_xXAnticoagulation with Lovenox (enoxaparin) is permitted, however, patients on anticoagulation with warfarin are not permitted on this studyXx_NEWLINE_xXOral anticoagulants such as warfarin are cytochrome P450 family 2, subfamily C, polypeptide 9 (CYP2C9) substrates and, as such, no interaction with everolimus is expected; anticoagulation with Coumadin is allowed if target INR is =< 2.0 and stable for > 2 weeks; anticoagulation with low-molecular-weight heparin (LMWH) is allowedXx_NEWLINE_xXPatients who require heparin (other than low-molecular weight heparin)Xx_NEWLINE_xXPatients receiving warfarin (Coumadin®)Xx_NEWLINE_xXInability to comply with an anti-thrombotic treatment regimen (e.g., administration of aspirin, enoxaparin, or low molecular weight heparin administration [type Innohep or equivalent])Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.6 (unless receiving anticoagulation therapy); patients on full-dose anticoagulation must be on a stable dose (minimum duration 14 days) of oral anticoagulant or low molecular weight heparin; if receiving warfarin, the patient must have an INR =< 3.0 and no active bleeding (i.e., no bleeding within 14 days prior to first dose of study therapy)Xx_NEWLINE_xXIs unable or unwilling to undergo thromboembolic prophylaxis including, as clinically indicated, aspirin, Coumadin (warfarin) or low-molecular weight heparin.Xx_NEWLINE_xXInability to comply with an anti-thrombotic treatment regimen (e.g., administration of aspirin, enoxaparin, or low molecular weight heparin administration)Xx_NEWLINE_xXAnti-coagulation therapy. Aspirin, other anti-platelet agents, and low molecular weight heparin are permitted unless the investigator deems the patient is at a significant risk for bleeding.Xx_NEWLINE_xXAnticoagulation with warfarinXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5, and a partial thromboplastin time (PTT) =< 5 seconds above the ULN (unless receiving anticoagulation therapy); patients receiving warfarin must be switched to low molecular weight heparin and have achieved stable coagulation profile prior to first dose of protocol therapyXx_NEWLINE_xXCurrent therapeutic anticoagulation with warfarin (or coumarin derivatives)Xx_NEWLINE_xXConcomitant anticoagulation, at therapeutic doses, with anticoagulants.Xx_NEWLINE_xXRequires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists within 7 days of first dose of study drug.Xx_NEWLINE_xXRequires or receiving anticoagulation with warfarin or equivalent vitamin K antagonists within 7 days of first dose of study drug.Xx_NEWLINE_xXconcomitant use of warfarin or other Vitamin K antagonistsXx_NEWLINE_xXSubject is currently receiving warfarin or other Coumarin derived anti-coagulant for treatment; therapy with heparin, low molecular weight heparin (LMWH), factor Xa, or fondaparinux is allowedXx_NEWLINE_xXRequired concurrent use of anti-coagulants or anti-platelet medication, with the exception of aspirin doses ?81 mg/day, low-dose SC heparin or SC low-molecular-weight heparin for DVT prophylaxis, or heparin flushes to maintain IV catheter patencyXx_NEWLINE_xXConcomitant anticoagulation with oral anticoagulants (eg, warfarin, direct thrombin, and factor Xa inhibitors) or platelet inhibitors (eg, clopidogrel); Note: low-dose aspirin for cardioprotection (per local applicable guidelines) and low dose, low molecular weight heparins (LMWH) are permitted; anticoagulation with therapeutic doses of LMWH is allowed in subjects without radiographic evidence of brain metastasis, who are on a stable dose of LMWH for at least 6 weeks before the first dose of study treatment, and who have had no complications from a thromboembolic event or the anticoagulation regimenXx_NEWLINE_xXConcomitant anticoagulation with oral anticoagulants (eg, warfarin, direct thrombin, and factor Xa inhibitors) or platelet inhibitors (eg, clopidogrel); note: low-dose aspirin for cardioprotection (per local applicable guidelines) and low dose, low molecular weight heparins (LMWH) are permitted; anticoagulation with therapeutic doses of LMWH is allowed in subjects without radiographic evidence of brain metastasis, who are on a stable dose of LMWH for at least 6 weeks before the first dose of study treatment, and who have had no complications from a thromboembolic event or the anticoagulation regimenXx_NEWLINE_xXOngoing treatment with therapeutic doses of warfarin or low molecular weight heparin (low dose warfarin up to 2 mg orally [PO] daily or use of subcutaneous low molecular weight heparin for thromboembolic prophylaxis is allowed)Xx_NEWLINE_xXParticipant is currently on medications that interfere with coagulation (including warfarin) or platelet function with the exception of low dose aspirin (up to 100 mg) and Low-molecular-weight heparin.Xx_NEWLINE_xXRequires anti-coagulation with warfarin or a vitamin K antagonistXx_NEWLINE_xXAnticoagulation/antiplatelet therapy within 7 days of Cycle 1 Day 1, including low molecular weight heparin, or warfarin.Xx_NEWLINE_xXRequirement for chronic anticoagulation with warfarin or with direct oral anticoagulants at the time of screening.Xx_NEWLINE_xXPatient is currently receiving warfarin or other Coumarin-derived anticoagulant for treatment, prophylaxis or otherwise; NOTE: therapy with apixaban, dabigatran, heparin, low molecular weight heparin (LMWH) or fondaparinux is allowedXx_NEWLINE_xXPatients must be able to start low-molecular weight heparin, as prophylaxisXx_NEWLINE_xXPatients are excluded if they have current, ongoing treatment with full-dose warfarin or its equivalent (i.e., unfractionated and/or low molecular weight heparin); subjects should have not taken full-dose warfarin or equivalent for at least 2 weeks prior to randomizationXx_NEWLINE_xXPatient must be able and willing to receive anticoagulation therapy with aspirin 70-325 mg daily prophylaxis, low molecular weight heparin, factor X inhibitors or warfarin; patients unable or unwilling to take any prophylaxis are NOT eligibleXx_NEWLINE_xXCurrent use of anticoagulants (e.g., warfarin, heparin) at therapeutic levels within 7 days prior to the first dose of GSK525762. Low dose (prophylactic) low molecular weight heparin (LMWH) is permitted. In addition, INR must be monitored in accordance with local institutional practices.Xx_NEWLINE_xXInternational normalized ratio of prothrombin time must be less than or equal to 1.5 times the ULN. Patients who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate if no underlying abnormality in coagulation parameters exists per medical history.Xx_NEWLINE_xXSUB-PROTOCOL AIM A: Adequate coagulation function as defined by either of the following criteria:\r\n* International normalized ratio (INR) =< 1.5 x ULN\r\n* For subjects receiving warfarin or low molecular weight heparin (LMWH), the subjects must, in the investigator’s opinion, be clinically stable with no evidence of active bleeding while receiving anticoagulant therapy; the INR for these patients may exceed 1.5 x ULN if that is the goal of the anticoagulant therapyXx_NEWLINE_xXConcomitant use of anticoagulants including warfarin, other vitamin K antagonists, and enoxaparinXx_NEWLINE_xXMust be able to take low-dose aspirin, low molecular weight heparin, or other equivalent antithrombotic or anticoagulant daily as prophylactic anticoagulation.Xx_NEWLINE_xXSubjects receiving heparin, warfarin, or other similar anticoagulants, except for subjects on low molecular weight heparin for DVT/PE prophylaxis. Note: Subjects may be receiving low-dose aspirin and/or non-steroidal anti-inflammatory agents.Xx_NEWLINE_xXPatients on Warfarin/Dabigatran/Rivaroxaban anticoagulation may be enrolled for as long as they undergo weekly INR checks for the first 2 months of therapy. a. Patients who switch to low molecular weight heparin may be enrolled and weekly INR labs are not mandated for these patients.Xx_NEWLINE_xXNo use of warfarin or similar vitamin K antagonistsXx_NEWLINE_xXConcomitant use of warfarin or other vitamin K antagonistsXx_NEWLINE_xXAble to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to acetylsalicylic acid [ASA] may use low molecular weight heparin)Xx_NEWLINE_xXAnticoagulation/antiplatelet therapy within 7 days of C1D1, including acetylsalicylic acid, low molecular weight heparin, or warfarinXx_NEWLINE_xXChronic anticoagulation, not including aspirin, but including heparins, warfarin, oral anticoagulation or other platelet function inhibitors, that can not, in the documented opinion of the investigator, safely be interrupted from at least 2 days prior to the initiation of the study regimen until after surgical resection of the tumor.Xx_NEWLINE_xXPatient is currently receiving warfarin or other coumadin-derived anticoagulant for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowedXx_NEWLINE_xXTreatment by warfarin or equivalent vitamin K antagonists.Xx_NEWLINE_xXConcomitant use of warfarin or other vitamin K antagonistsXx_NEWLINE_xXpatients on anticoagulants for whom temporarily stop and start, supported by low molecular weight heparin (or other anticoagulation therapy at the discretion of the investigator and or per local standard of care) during vaccination and nephrectomy, is not an optionXx_NEWLINE_xXTherapeutic anticoagulation with Vitamin-K antagonists (eg, warfarin) or with heparins and heparinoids. o However, prophylactic anticoagulation as described below is allowed:Xx_NEWLINE_xXLow dose warfarin (1 mg orally, once daily) with PT-INR ? 1.5 x ULN is permitted. Infrequent bleeding or elevations in PT-INR have been reported in some subjects taking warfarin while on regorafenib therapy. Therefore, subjects taking concomitant warfarin should be monitored regularly for changes in PT, PT-INR, or clinical bleeding episodes.Xx_NEWLINE_xXProphylactic doses of heparin.Xx_NEWLINE_xXThe concomitant use of warfarin or other vitamin K antagonists unless felt to be of significant clinical need; low molecular weight heparin or other anticoagulants may be used instead if anticoagulation is requiredXx_NEWLINE_xXCoagulation • INR less than or equal to 1.5 x ULN (or in range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin).Xx_NEWLINE_xXInternational normalized ratio (INR) </= 2 and a partial thromboplastin time (PTT) </= 5 seconds above the ULN (unless on oral anticoagulant therapy). Patients receiving full dose anticoagulation therapy are eligible provided they meet all other criteria, are on a stable dose of oral anticoagulant or low molecular weight heparin (except warfarin or coumarin-like anticoagulants, which are not permitted).Xx_NEWLINE_xXCurrent treatment with warfarin; for patients not on an anti-platelet agent such as aspirin, other anticoagulation is acceptable so long as the treating physician feels that it is safe to hold it on the day of the biopsy until after the biopsy has been safely completedXx_NEWLINE_xXUse or need for full dose anticoagulation other than low molecular weight heparin and factor Xa inhibitors (e.g. Lovenox, fondaparinux) and no other bleeding riskXx_NEWLINE_xXCurrent use or anticipated need for treatment with Coumadin® or other agents containing warfarin (except low dose Coumadin [1 mg or less daily] administered prophylactically for maintenance of in-dwelling lines or ports); heparin, low molecular weight heparin (LWMH), direct thrombin inhibitors and factor Xa inhibitors are allowed; rivaroxaban should be used with caution; antiplatelet agents are allowedXx_NEWLINE_xXPatients must not be receiving active systemic anticoagulation with heparin or warfarin; patients must be off warfarin therapy for at least 30 days prior to enrollmentXx_NEWLINE_xXPatients currently taking anticoagulants (warfarin, heparin/low molecular weight heparin [e.g., danaparoid, dalteparin, tinzaparin, enoxaparin])Xx_NEWLINE_xXBleeding or thrombotic disorders or use of anticoagulants requiring therapeutic INR monitoring, eg, warfarin or similar agents. Treatment with low molecular weight heparin and factor X inhibitors which do not require INR monitoring is permitted. Antiplatelet agents are prohibited throughout the study.Xx_NEWLINE_xXThe subject requires treatment, in therapeutic doses, with oral anticoagulants such as warfarin prior to initiation of protocol therapy; low dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day), and low molecular weight heparin (LMWH) are permitted; subjects will be permitted to use anticoagulation if treatment is required while they are enrolled on the protocolXx_NEWLINE_xXPatients on full-dose anticoagulants (e.g., warfarin or low molecular weight [LMW] heparin) must have no active bleeding or pathological condition that carries a high risk of bleeding, and must be on a stable dose of oral anticoagulant for 14 days or on a stable dose of low molecular weight heparin for 14 daysXx_NEWLINE_xXPatients must have no medical contra-indications to, and be willing to take, deep vein thrombosis (DVT) prophylaxis as all patients registering to the lenalidomide/rituximab Arms G and H will be required to have deep vein thrombosis (DVT) prophylaxis; patients randomized to Arms G or H who have a history of a thrombotic vascular event will be required to have full anticoagulation, therapeutic doses of low-molecular weight heparin or warfarin to maintain an international normalized ratio (INR) between 2.0-3.0, or any other accepted full anticoagulation regimen (e.g., direct thrombin inhibitors or factor Xa inhibitors) with appropriate monitoring for that agent; patients on Arms G and H without a history of a thromboembolic event are required to take a daily aspirin (81 mg or 325 mg) for DVT prophylaxis; patients who are unable to tolerate aspirin should receive low molecular weight heparin therapy or warfarin treatment or another accepted full anticoagulation regimenXx_NEWLINE_xXPatients must have no medical contra-indications to, and be willing to take, DVT prophylaxis as all patients registering to the lenalidomide/rituximab Arms G and H will be required to have deep vein thrombosis (DVT) prophylaxis; patients randomized to Arms G or H who have full anticoagulation, a history of a thrombotic vascular event will be required to have therapeutic doses of low molecular weight heparin or warfarin to maintain an INR between 2.0 – 3.0, or any other accepted full anticoagulation regimen (e.g., direct thrombin inhibitors or factor Xa inhibitors) with appropriate monitoring for that agent; patients on Arms G and H without a history of a thromboembolic event are required to take a daily aspirin (81 mg or 325 mg) for DVT prophylaxis; patients who are unable to tolerate aspirin should receive low molecular weight heparin therapy or warfarin treatment or another accepted full anticoagulation regimenXx_NEWLINE_xXFor patients requiring anti-coagulation therapy, only therapeutic low molecular weight heparin, direct thrombin inhibitors, or factor Xa inhibitors are permittedXx_NEWLINE_xXPatients who are currently receiving therapeutic anticoagulants (including aspirin, low molecular weight heparin, warfarin and others) are not eligibleXx_NEWLINE_xXParticipant must have adequate coagulation function as defined by international normalized ratio (INR) ? 1.5 and a partial thromboplastin time (PTT) ? 1.5 X ULN if not receiving anticoagulation therapy. Participants on full-dose anticoagulation must be on a stable dose of oral anticoagulant or low molecular weight heparin and if on warfarin must have a INR between 2 and 3 and have no active bleeding (defined as within 14 days of randomization) or pathological condition that carries a high risk of bleeding (such as, tumor involving major vessels or known varices)Xx_NEWLINE_xXINR and aPTT ? 1.5 x ULN • This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation (such as low-molecular-weight heparin or warfarin) should be on a stable dose.Xx_NEWLINE_xXCurrent use of warfarin, factor Xa inhibitors and direct thrombin inhibitors\r\n* Note: Low molecular weight heparin and prophylactic low dose warfarin are permitted; PT/PTT must meet the inclusion criteria; subjects taking warfarin must have their INR followed closelyXx_NEWLINE_xXFor patients not taking warfarin: INR ?1.5 or PT ?1.5 × ULN; and either PTT or aPTT ?1.5 × ULN. Patients taking warfarin should be on a stable dose that results in a stable INR <3.5.Xx_NEWLINE_xXPatient is currently receiving warfarin or other coumarin-derived anticoagulant for treatment, prophylaxis or otherwise; therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowedXx_NEWLINE_xXUse of warfarin is prohibited; anticoagulation with low-molecular weight heparin (i.e. enoxaparin) or direct thrombin inhibitors is permittedXx_NEWLINE_xXPatient is currently receiving warfarin or other coumarin-derived anticoagulant for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowed.Xx_NEWLINE_xXInternational normalized ratio (INR) and activated partial thromboplastin time aPTT =< 1.5 x ULN (This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation, such as low-molecular-weight heparin or warfarin, should be on a stable dose)Xx_NEWLINE_xXTherapeutic anticoagulation (except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous devise) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid < 325 mg per day)Xx_NEWLINE_xXCurrent therapy with warfarin or other anticoagulants at therapeutic doses, e.g., low molecular weight heparin, fondaparinux, dabigatran, rivaroxaban, apixaban or edoxaban that are unable to be discontinuedXx_NEWLINE_xXTherapeutic anticoagulation with vitamin-K antagonists (e.g., warfarin) is not allowed if the medication dose and/or international normalized ratio (INR)/partial thromboplastin time (PTT) are not considered stable by the treating physician; if the dose and/or INR/PTT are stable, therapeutic anticoagulation with vitamin-K antagonists is allowed with close monitoring; anticoagulation with heparin or heparinoids is allowedXx_NEWLINE_xXPatient is currently receiving warfarin or other vitamin K antagonist; therapy with heparin, low molecular weight heparin (LMWH), or fondaparinux is allowedXx_NEWLINE_xXTherapeutic anticoagulation (e.g., warfarin, heparin) must be discontinued and coagulation parameters must be normalized prior to the first dose of GSK2820151. Low dose (prophylactic) low molecular weight heparin (LMWH) is permitted. In addition, INR must be monitored in accordance with local institutional practices.Xx_NEWLINE_xXConcomitant use of warfarin or other vitamin K antagonistsXx_NEWLINE_xXRequirement for anticoagulation with warfarin or similar vitamin K antagonistsXx_NEWLINE_xXNo therapeutic anticoagulation (except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous device) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid < 325 mg per day); no history of clinically significant hemorrhagic or thromboembolic event in the past 6 monthsXx_NEWLINE_xXPatients receiving warfarin or other vitamin K antagonists; however, if therapeutic anticoagulation is necessary, low molecular weight heparin (LMWH) is the anticoagulant of choiceXx_NEWLINE_xXIf currently not on anticoagulation medication, willing and able to take aspirin (81 or 325 mg) daily; if aspirin is contraindicated, the patient may be considered for the study if on therapeutic dose warfarin or low molecular weight heparin; patients unable to take any prophylaxis are not eligibleXx_NEWLINE_xXRequires anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon); if patients have been on warfarin or equivalent vitamin K antagonists in the past, they will not be eligible if administered within 30 days of the first dose of study drugXx_NEWLINE_xXInternational normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN; this applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation (such as low-molecular weight heparin or warfarin) should be on a stable doseXx_NEWLINE_xXCurrent use of anticoagulants (warfarin, heparin, direct thrombin inhibitors) at therapeutic levelsXx_NEWLINE_xXCurrent use of warfarin (patients will be eligible if warfarin is discontinued and low-molecular weight heparin is used instead)Xx_NEWLINE_xXPatients on full-dose anticoagulants (e.g., warfarin or low molecular weight [LMW] heparin) must meet the following criteria:\r\n* No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)Xx_NEWLINE_xXPatients who require warfarin anticoagulation or who have received warfarin or equivalent vitamin K antagonists =< 7 days prior to treatment day 1; patients may be eligible if able to be taken off warfarin and started on an alternative anticoagulantXx_NEWLINE_xXPatient is currently receiving warfarin or other coumarin-derived anticoagulant for treatment, prophylaxis or otherwise; therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowedXx_NEWLINE_xXPatients taking warfarin or platelet inhibitorsXx_NEWLINE_xXOngoing therapy with oral or parenteral anticoagulants (e.g., heparin, warfarin); low-dose anticoagulants for maintenance of catheter patency are not exclusionaryXx_NEWLINE_xXContraindication or prior intolerance to thromboembolic prophylaxis with aspirin, warfarin or low-molecular weight heparinXx_NEWLINE_xXThe subject is receiving warfarin (or other coumarin derivatives) and is unable to switch to low molecular weight heparin (LMWH) before the first dose of study drugXx_NEWLINE_xXRequires therapeutic anticoagulation with warfarin at baseline; patients must be off warfarin or warfarin-derivative anti-coagulants for at least 7 days prior to starting study drug; however, therapeutic or prophylactic therapy with low-molecular weight heparin is allowedXx_NEWLINE_xXRequires treatment with anticoagulation with warfarin or equivalent vitamin K antagonistsXx_NEWLINE_xXTreatment with warfarin or other vitamin K antagonist; patients with using warfarin who switch to another form of anticoagulation will be eligibleXx_NEWLINE_xXThe subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or factor Xa inhibitors, or antiplatelet agents (e.g., clopidogrel); low dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are permittedXx_NEWLINE_xXCurrent therapeutic anticoagulation with Coumadin (warfarin)Xx_NEWLINE_xXPatient is using warfarin or any other Coumadin-derivative anticoagulant; patients must be off Coumadin-derivative anticoagulants for at least seven days prior to starting the study drug; low molecular weight heparin is allowedXx_NEWLINE_xXPartial thromboplastin time (PTT) =< 1 x institutional ULN and international normalized ratio (INR) =< 1.5 , unless participant is on full dose anticoagulation therapy obtained =<14 days prior to randomization; patients on full-dose anticoagulation are eligible if the following criteria are met:\r\n* Patient has an in-range INR (usually 2-3) on a stable dose of warfarin or other anticoagulant =< 14 days or is on a stable dose of low molecular weight heparin\r\n* Patient has no active bleeding or pathological condition that carries a high risk of bleeding (i.e., tumor involving major vessels or known varices)\r\n* Patients receiving anti-platelet agents are eligible; in addition, patients who are on daily prophylactic aspirin or anticoagulation for atrial fibrillation are eligibleXx_NEWLINE_xXPatient is currently receiving warfarin or other coumarin derived anti-coagulant, for treatment, prophylaxis or otherwise; therapy with heparin, low molecular weight heparin (LMWH), or fondaparinux is allowedXx_NEWLINE_xXPatients on full-dose anticoagulants (e.g., warfarin or low molecular weight [LMW] heparin) must have no active bleeding or pathological condition that carries a high risk of bleeding and must be on a stable dose of oral anticoagulant for 14 days or on a stable dose of low molecular weight heparin for 14 daysXx_NEWLINE_xXRequires anticoagulation with warfarin or equivalent vitamin K antagonistXx_NEWLINE_xXPatients who require warfarin for anticoagulation (other anticoagulants are allowed)Xx_NEWLINE_xXIf needed, patients should be able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulationXx_NEWLINE_xXRequires the use of warfarin, marcumar, or phenprocoumonXx_NEWLINE_xXPatients on warfarin for any reasonXx_NEWLINE_xXPatients who are currently taking therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulantXx_NEWLINE_xXConcomitant use of warfarin or other Vitamin K antagonistsXx_NEWLINE_xXPatients for whom prophylactic anticoagulation therapy (eg. 81 or 325 mg aspirin PO daily or warfarin (Coumadin) 1-2 mg/day, or any other coumarin-derivative anticoagulants) is not an option unless due to thrombocytopeniaXx_NEWLINE_xXInternational normalized ratio (INR), and prothrombin time (PT) =< 1.5 x upper limit of normal (ULN) (patients who are being prophylactically anticoagulated with an agent such as Coumadin or low molecular weight heparin [LMWH] or therapeutically anticoagulated with LMWH will be allowed to participate provided they are stable and monitored at appropriate intervals per institutional guidelines throughout study)Xx_NEWLINE_xXSubjects that have received anticoagulation therapy with warfarin or equivalent vitamin K antagonists within the last 28 days are not eligibleXx_NEWLINE_xXCurrently receiving treatment with therapeutic doses of warfarin sodium. Low molecular weight heparin is allowed.Xx_NEWLINE_xXPatients on therapeutic anticoagulation, with heparin (or low-molecular weight heparin), warfarin, or a direct thrombin inhibitor as the safety of concurrent administration of curcumin has not been establishedXx_NEWLINE_xXTherapeutic anticoagulation with vitamin-K antagonists (e.g., warfarin) is not allowed if the medication dose and/or international normalized ratio (INR)/partial thromboplastin time (PTT) are not considered stable by the treating physician; if the dose and/or INR/PTT are stable, therapeutic anticoagulation with vitamin-K antagonists is allowed with close monitoring; anticoagulation with heparin or heparinoids is allowedXx_NEWLINE_xXPatients who are currently taking therapeutic doses of warfarin sodium or any other Coumadin-derivative anticoagulant; patients who can be safely changed to enoxaparin or other non-warfarin derived anti-coagulant and who otherwise meet eligibility requirements may be enrolledXx_NEWLINE_xXPatients may not have received warfarin or another vitamin K antagonist in the preceding 30 daysXx_NEWLINE_xXAble to take aspirin, or warfarin, or low molecular weight heparin as prophylactic anticoagulationXx_NEWLINE_xXPatients receiving therapeutic doses of warfarin are not eligible for participation; Note: Patients with a need for therapeutic anticoagulation should be given low molecular weight heparin or other non-warfarin productXx_NEWLINE_xXThe subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or Factor Xa inhibitors, or antiplatelet agents (eg, clopidogrel); low dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are permittedXx_NEWLINE_xXThose who require therapeutic anticoagulation with coumarin-derivative anticoagulantsXx_NEWLINE_xXReceiving warfarin treatmentXx_NEWLINE_xXMust be able to take acetylsalicylic acid (ASA) (81 or 325 mg) daily as prophylactic anticoagulation. Patients intolerant to ASA may use low molecular weight heparin. Lovenox is recommended. Coumadin will be allowed provided the patient is fully anticoagulated, with an international normalized ratio (INR) of 2 to 3Xx_NEWLINE_xXRequires anticoagulation with warfarin or equivalent Vitamin K antagonistsXx_NEWLINE_xXRequirement of anticoagulant therapy with oral vitamin K antagonists; low-dose anticoagulants for maintenance of patency of central venous access devices or prevention of deep venous thrombosis is allowed; therapeutic use of low molecular weight heparin is allowedXx_NEWLINE_xXPatients must not be on phenytoin, warfarin or methadoneXx_NEWLINE_xXInternational normalized ratio (INR) and partial thromboplastin time (aPTT) ? 1.5 x ULN\r\n* This applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation (such as low-molecular-weight heparin or warfarin) should be on a stable doseXx_NEWLINE_xXAll study participants must be able to tolerate one of the following thromboprophylactic strategies: aspirin, low molecular weight heparin or warfarin (coumadin) or alternative anti-coagulantXx_NEWLINE_xXPatients requiring any therapeutic anticoagulation are excluded; patients who have received warfarin or other vitamin K antagonists within 28 days or are taking warfarin or other vitamin K antagonists are not eligibleXx_NEWLINE_xXPatients requiring full therapeutic anticoagulation with warfarin are ineligible because therapy on this trial may result in frequent and recurrent thrombocytopenia; full therapeutic anticoagulation with heparin, low molecular weight heparin, or direct factor Xa inhibitor is permittedXx_NEWLINE_xXPatients requiring full therapeutic anticoagulation including warfarin, heparin, low-molecular weight heparin, or direct factor Xa inhibitor are ineligible because therapy on this trial may result in frequent and recurrent thrombocytopenia; patients requiring prophylactic dose anticoagulation may be eligible after discussion with the principal investigatorXx_NEWLINE_xXWarfarin use is provisionally allowedXx_NEWLINE_xXPatients NOT on warfarin must have a prothrombin time (PT)/international normalized ratio (INR) < 1.4 within 14 days prior to registration\r\n* Patients on full-dose anticoagulants (e.g., warfarin or low molecular weight [LMW] heparin) must meet BOTH of the following criteria within 14 days prior to registration:\r\n** No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)\r\n** In-range INR (between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of LMW heparinXx_NEWLINE_xXRequires or is receiving anticoagulation with warfarin or equivalent vitamin K antagonists (e.g.: phenprocoumon) within 28 days of the first dose of study drugXx_NEWLINE_xXBleeding or thrombotic disorders or use of anticoagulants such as warfarin or similar agents requiring therapeutic international normalized ratio (INR) monitoring. (Treatment with low molecular weight heparin is allowed.)Xx_NEWLINE_xXCurrent therapeutic anticoagulation with warfarin (or coumarin derivatives)Xx_NEWLINE_xXRequires anticoagulation with warfarin or equivalent vitamin K antagonistsXx_NEWLINE_xXParticipants requiring the use of therapeutic doses of warfarin (Coumadin)Xx_NEWLINE_xXPatients on therapeutic anticoagulation with low molecular weight heparins, fondaparinux, rivaroxaban or warfarin are eligible, provided that they are on a stable dose of anticoagulants; patients who are currently receiving antiplatelet therapy of prasugrel or clopidogrel or antiaggregation agents (e.g., eptifibatide, epoprostenol, dipyridamole) or low doses of acetylsalicylic acid (up to 100 mg daily) are also eligibleXx_NEWLINE_xXPatients on active therapeutic anticoagulationXx_NEWLINE_xXCurrent treatment with warfarinXx_NEWLINE_xXPatients who are currently taking therapeutic doses of warfarin sodium or any other Coumadin-derivative anticoagulantXx_NEWLINE_xXContraindication to any of the required concomitant drugs, including proton-pump inhibitor (eg, lansoprazole), enteric-coated aspirin, allopurinol or if a history of prior thrombotic disease, warfarin or low molecular weight heparinXx_NEWLINE_xXTreatment with therapeutic doses of coumarin-type anticoagulants (maximum daily dose of 1 mg allowed for port line patency permitted); low molecular weight heparin (LMWH) will be allowedXx_NEWLINE_xXTherapeutic anticoagulation with vitamin-K antagonists (e.g., warfarin) or with heparins and heparinoids\r\n* However, prophylactic anticoagulation as described below is allowed:\r\n** Low dose warfarin (1 mg orally, once daily) with prothrombin time (PT)-international normalized ratio (INR) =< 1.5 x upper limit of normal (ULN) is permitted; subjects taking concomitant warfarin should be monitored regularly for changes in PT, PT-INR or clinical bleeding episodes\r\n** Prophylactic doses of heparinXx_NEWLINE_xXCurrent use of therapeutic anticoagulants such as warfarin or heparinXx_NEWLINE_xXPatients who participate in this study must be willing and able to tolerate prophylactic anticoagulation either with aspirin, low-molecular weight heparin (LMWH), or warfarinXx_NEWLINE_xXPatients on full-dose anticoagulants (e.g., warfarin or low molecular weight [LMW] heparin) must meet both of the following criteria:\r\n* No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)\r\n* In-range international normalized ratio (INR) (usually between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin, within 14 days prior to registrationXx_NEWLINE_xXAble to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to acetylsalicylic acid [ASA] may use warfarin or low molecular weight heparin)Xx_NEWLINE_xXPatient is receiving warfarin (Coumadin)Xx_NEWLINE_xXAble to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to acetylsalicylic acid [ASA] may use warfarin or low molecular weight heparin), unless baseline prothrombin time (PT) or partial thromboplastin time (PTT) is >= 1.5 ULN, in which case thromboprophylaxis is not requiredXx_NEWLINE_xXReceiving warfarinXx_NEWLINE_xXPatients with an active bleeding tendency or are receiving any treatment with therapeutic doses of sodium warfarin (Coumadin) or coumadin derivatives; patients will be allowed to enter study on aspirin doses of 81 mg/dXx_NEWLINE_xXThe subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or factor Xa inhibitors, or antiplatelet agents (e.g., clopidogrel); low dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are permittedXx_NEWLINE_xXAnticoagulants other than low molecular weight heparin.Xx_NEWLINE_xXHistory of pulmonary embolus within 3 months or deep venous thrombosis (DVT) within 4 weeks of enrollment; patients on anticoagulation must be on a stable dose of warfarin with a therapeutic-range international normalized ratio (INR) or on a stable dose of low molecular weight heparinXx_NEWLINE_xXPatients on vitamin K antagonist warfarinXx_NEWLINE_xXOngoing therapy with oral or parenteral anticoagulants; low-dose anticoagulation to maintain patency of lines is allowedXx_NEWLINE_xXPatients who require therapeutic doses of Coumadin derivative anticoagulants such as warfarin are excluded; low molecular weight heparin is permitted, provided the patient’s PT/INR is =< 1.5; Coumadin doses of up to 2 mg daily are permitted for prophylaxis of thrombosisXx_NEWLINE_xXPatients who require use of therapeutic doses of coumarin-derivative anticoagulants such as warfarin are excluded, although doses of up to 2 mg daily are permitted for prophylaxis of thrombosis; note: low molecular weight heparin is permitted provided the patient’s PT INR is =< 1.5Xx_NEWLINE_xXRequires anticoagulation with warfarin or equivalent vitamin K antagonists or treatment with strong CYP3A4/5 inhibitorsXx_NEWLINE_xXStable dose Coumadin anticoagulation is allowed, providing that anticoagulation can be safely held to an international normalized ratio (INR) within normal range for the purpose of tumor biopsy; low molecular weight heparin (LMWH) is the preferred method of anticoagulationXx_NEWLINE_xXThe participant requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or factor Xa (FXa) inhibitors, or antiplatelet agents (e.g., clopidogrel); low dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are permittedXx_NEWLINE_xXPatients on warfarin will be excluded from the trial if they cannot be switched to an acceptable alternative medication (i.e. low molecular weight heparin [LMWH]); prolongation of prothrombin time (PT) and International Normalized Ratio (INR) were observed in patients receiving vorinostat concomitantly with coumarin-derivative anticoagulantsXx_NEWLINE_xXAble to take acetylsalicylic acid (ASA) (81 or 325 mg) daily as prophylactic anticoagulation. Patients intolerant to ASA may use low molecular weight heparin. Lovenox is recommended. Coumadin will be allowed provided the patient is fully anticoagulated, with an INR of 2 or 3.Xx_NEWLINE_xXPatients must not have any evidence of bleeding diathesis or be on any therapeutic anticoagulation such as low molecular weight (LMW) heparin or warfarin for deep vein thrombosis (DVT) treatmentXx_NEWLINE_xXMust have been able to take concurrent aspirin 81 to 325 mg daily (or enoxaparin 40 mg subcutaneously daily [or its equivalent] if allergic to aspirin), per published standard or institutional standard of care, as prophylactic anticoagulation. NOTE: For participants with prior history of deep vein thrombosis (DVT), low-molecular-weight heparin (LMWH) was mandatory.Xx_NEWLINE_xXPatients on therapeutic dose anti-coagulation with warfarin, low molecular weight heparin (LMWH), or other anti-coagulants will be allowed to participate in the study; however, the anti-coagulants should be held pre- and post- research biopsy (when applicable) as per institutional standards; the risks of a temporary hold of anti-coagulation should be carefully considered and explained to the patient as part of the informed consent process; if it is not felt to be in the best interest of the patient to have anti-coagulation held, the patient may still enter the study, but should not undergo a research biopsyXx_NEWLINE_xXInternational normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.5; anticoagulation is allowed if target INR =< 1.5 on a stable dose of warfarin or on a stable dose of low-molecular weight (LMW) heparin for > 2 weeks at time of randomizationXx_NEWLINE_xXAble to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to aspirin may use warfarin or low molecular weight heparin)Xx_NEWLINE_xXContraindication to aspirin; if unable to take aspirin, contraindication to warfarin or low molecular weight heparinXx_NEWLINE_xXWarfarin is not permittedXx_NEWLINE_xXCurrent, ongoing treatment with full-dose warfarin; however patients may be on stable doses of a low molecular weight heparin are allowed (i.e. Lovenox)Xx_NEWLINE_xXPatients on full-dose anticoagulation are eligible if the following criteria are met:\r\n* Patient has an in-range international normalized ratio (INR) (usually 2-3) on a stable dose of warfarin or is on a stable dose of low molecular weight heparin\r\n* Patient has no active bleeding or pathological condition that carries a high risk of bleeding (i.e., tumor involving major vessels or known varices) \r\n* Patients receiving anti-platelet agents are eligible; in addition, patients who are on daily prophylactic aspirin or anticoagulation for atrial fibrillation are eligibleXx_NEWLINE_xXAble to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to aspirin [ASA] may use warfarin or low molecular weight heparin)Xx_NEWLINE_xXThrombolytics or treatment doses of warfarin within 28 days of initiating treatment; patients who require low dose warfarin for central venous catheter patency are allowed to enter if their dose is < 2 mg per day total AND their international normalized ratio (INR) is =< 1.5Xx_NEWLINE_xXPatients requiring treatment doses of heparin for any reason; the use of heparin flushes for maintenance of central venous catheters is permittedXx_NEWLINE_xXPatients requiring warfarin/Coumadin for therapeutic anticoagulation; low molecular weight heparin is allowedXx_NEWLINE_xXAble to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin).Xx_NEWLINE_xXThe subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or Coumadin-related agents, heparin, thrombin or factor Xa (FXa) inhibitors, and antiplatelet agents (eg, clopidogrel); low dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are permittedXx_NEWLINE_xXActive bleeding diathesis or current treatment with therapeutic doses of sodium warfarin (Coumadin) or other vitamin K active agents (Note: mini-dose of Coumadin (e.g., 1 mg/day) or anti-coagulants given to maintain intravenous line patency, as well as unfractionated or low molecular weight heparin therapy are permitted)Xx_NEWLINE_xXSubjects who require heparin other than low-molecular weight heparinXx_NEWLINE_xXAble to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to acetylsalicylic acid [ASA] may use warfarin or low molecular weight heparin)Xx_NEWLINE_xXPatients currently requiring anticoagulation with coumadin (nonsteroidal anti-inflammatory drugs [NSAIDs] and prophylactic dose heparin are allowed)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.2 x ULN; partial thromboplastin time (PTT) =< 1.5 x ULN, within 14 days of registration; therapeutic anticoagulation with warfarin is allowed if target INR =< 3 on a stable dose of warfarin or on a stable dose of low molecular weight (LMW) heparin for > 2 weeks (14 days) at time of randomizationXx_NEWLINE_xXAble to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation. Patients intolerant to ASA may use low molecular weight heparin. Lovenox is recommended. Coumadin will be allowed provided the patient is fully anticoagulate with INR 2.0 to 2.5.Xx_NEWLINE_xXAnti-coagulation at baseline:\r\n* For the first 20 patients to register to trial, no anti-coagulation is allowed; patients requiring therapeutic anticoagulation with warfarin or therapeutic or prophylactic therapy with a low-molecular weight heparin at baseline are excluded\r\n* For all subsequent patients screened, patients requiring therapeutic anticoagulation with warfarin at baseline are excluded; however, therapeutic or prophylactic therapy with a low-molecular weight heparin at baseline is acceptableXx_NEWLINE_xXInternational normalized ratio (INR) =< 2.0; anticoagulation is allowed if target INR =<, 2.0 on a stable dose of warfarin or if patient on a stable dose of low molecular weight (LMW) heparin for > 1 weeks at time of enrollmentXx_NEWLINE_xXPatients with an active, bleeding diathesis or on oral anti-vitamin K medication (except low-dose warfarin and aspirin or equivalent, as long as the INR =< 2.0)Xx_NEWLINE_xXActive bleeding tendency; NOTE: patients on therapeutic anticoagulation should be monitored carefully to maintain therapeutic level of anticoagulation to avoid increased risk of bleeding due to concurrent drug induced thrombocytopenia; it is suggested that patients who require anticoagulation therapy while on therapy use low molecular weight heparin (LMWH)Xx_NEWLINE_xXPatient must be able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to acetylsalicylic acid [ASA] may use warfarin or low molecular weight heparin)Xx_NEWLINE_xXAble to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to acetylsalicylic acid [ASA] may use warfarin or low molecular weight heparin) if no additional risk factor for venous thromboembolism (VTE) other than myeloma diagnosis according to International Myeloma Working Group (IMW) guidelinesXx_NEWLINE_xXAble to take low molecular weight heparin or warfarin if >= 1 additional risk factor for VTE according to IMW guidelinesXx_NEWLINE_xXPatients receiving current, ongoing treatment with full-dose warfarin or its equivalent (i.e., unfractionated and/or low molecular weight heparin) are NOT excludedXx_NEWLINE_xXAble to take aspirin (81 or 325mg) daily as prophylactic anticoagulation (patients intolerant to ASA may use warfarin or low molecular weight heparin)Xx_NEWLINE_xXInternational normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN (this applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation, such as low-molecular-weight heparin or warfarin, should be on a stable dose)Xx_NEWLINE_xXClinically significant bleeding within 4 weeks of screening, current use of warfarin, factor Xa inhibitors, and direct thrombin inhibitors unless these medications can be safely discontinued 14 days prior to AMG-232 administration; Note: low molecular weight heparin and prophylactic low dose warfarin are permitted; PT/PTT must meet the inclusion criteria; subjects taking warfarin must have their INR followed closelyXx_NEWLINE_xXConcomitant anticoagulation with oral anticoagulants.Xx_NEWLINE_xXOR for subjects receiving warfarin or low molecular weight heparin (LMWH), the subjects must, in the Investigator's opinion, be clinically stable with no evidence of active bleeding while receiving anticoagulant therapy. The INR for these subjects may exceed 1.5 × ULN if that is the goal of anticoagulant therapy.Xx_NEWLINE_xXConcurrent use of warfarin or other vitamin K antagonistsXx_NEWLINE_xXAll study participants must be able to tolerate one of the following thromboprophylactic strategies: aspirin, low molecular weight heparin or warfarin (Coumadin) or alternative anti-coagulantXx_NEWLINE_xXAble to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (subjects intolerant to acetylsalicylic acid [ASA] may use warfarin or low molecular weight heparin)Xx_NEWLINE_xXPatients on chronic anticoagulation such as Aspirin, Plavix, or Coumadin who cannot have anticoagulation held for procedures are not eligibleXx_NEWLINE_xXAble to take aspirin 325 mg or 81 mg daily as prophylactic anticoagulation (patients intolerant to acetylsalicylic acid [ASA] may use Coumadin or low molecular weight heparin)Xx_NEWLINE_xXHistory of adverse reaction to heparin such as heparin-induced thrombocytopeniaXx_NEWLINE_xXTreatment with warfarin, clopidogrel, aspirin, NSAIDs, LMWH or other anti-coagulants for conditionsXx_NEWLINE_xXTherapeutic anticoagulation with warfarin, heparins, or heparinoidsXx_NEWLINE_xXPatients requiring anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon) within 28 days from the start of study drug cannot be treated with ibrutinib but idelalisib would be an optionXx_NEWLINE_xXRequires anticoagulation with warfarin or equivalent vitamin K antagonistsXx_NEWLINE_xXAble to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to acetylsalicylic acid [ASA] may use warfarin or low molecular weight heparin)Xx_NEWLINE_xXRequires anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon), direct thrombin inhibitors, direct factor Xa inhibitors or heparin or low-molecular weight heparins at therapeutic dosesXx_NEWLINE_xXWeight of at least 10kg.Xx_NEWLINE_xXThis applies only to patients who do not receive therapeutic anticoagulation; patients receiving therapeutic anticoagulation (such as low molecular weight heparin or warfarin) should be on a stable dose.Xx_NEWLINE_xXTherapeutic anticoagulation (e.g. warfarin, heparin, etc.) must be stopped at least 7 days prior to the first dose of MK-8628. Low-dose low molecular weight heparin (LMWH) is permittedXx_NEWLINE_xXConcomitant use of warfarin or other vitamin K antagonists (for patients who are discontinuing warfarin or other vitamin K antagonists, a wash-out period of 5 effective half-lives is required prior to 1st dose of ibrutinib)Xx_NEWLINE_xXIf on anticoagulation, participant must be on stable therapeutic dose prior to enrollmentXx_NEWLINE_xXCurrently receiving treatment with therapeutic doses of warfarin sodium. Low molecular weight heparin and oral Xa inhibitors are allowed.Xx_NEWLINE_xXUse of warfarin, factor Xa inhibitors, or direct thrombin inhibitorsXx_NEWLINE_xXTherapeutic anticoagulation (except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous devise) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid < 325 mg per day)Xx_NEWLINE_xXConcomitant use of warfarin or other Vitamin K antagonists.Xx_NEWLINE_xXPatients who are currently taking therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulant; low molecular weight heparin is allowedXx_NEWLINE_xXConcomitant use of warfarin or other vitamin K antagonistsXx_NEWLINE_xXOngoing anticoagulant therapy (eg, aspirin, coumadin, heparin).Xx_NEWLINE_xXOngoing anticoagulant therapy (eg, aspirin, coumadin, heparin).Xx_NEWLINE_xXParticipants who require anticoagulation should receive low-molecular weight or standard heparin and not warfarinXx_NEWLINE_xXReceived anticoagulation therapy with warfarin or equivalent vitamin K antagonists within the last 28 daysXx_NEWLINE_xXAnticoagulation with warfarin or equivalent vitamin K antagonists within 28 days prior to starting ibrutinib and throughout the studyXx_NEWLINE_xXConcurrent use of therapeutic warfarin is allowed. However, anticoagulants that do not have reversal agents available are prohibited.Xx_NEWLINE_xXPatients on warfarin will not be allowed on the study; patient on low molecular heparin or anti direct factor Xa inhibitor (Xa) drugs will be allowedXx_NEWLINE_xXOngoing treatment with therapeutic doses of warfarin (low dose warfarin up to 2 mg orally [PO] daily for thromboembolic prophylaxis is allowed)Xx_NEWLINE_xXPatients who are receiving therapeutic anticoagulation with heparin are allowed to participate provided that no prior evidence of underlying abnormality exists in these parameters; patients on warfarin are eligible provided they are on stable doses of warfarin and there is close monitoring of international normalized ratio (INR)Xx_NEWLINE_xXCurrent use of therapeutic anticoagulation therapyXx_NEWLINE_xXUse of warfarin is not allowed; patient is recommended to switch to low molecular weight heparin (LMWH) before participating in this studyXx_NEWLINE_xXThe subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or Factor Xa inhibitors, or antiplatelet agents (eg, clopidogrel); low dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are permittedXx_NEWLINE_xXUse of warfarin, metronidazole or ornidazole for therapeutic useXx_NEWLINE_xXHad full-dose anticoagulation with heparin, enoxaparin, dalteparin, other LMWH, a/or other anticoagulants w/in 90 days before first dose of M402Xx_NEWLINE_xXPatients receiving therapeutic anticoagulation; prophylactic anticoagulation of venous access devices is allowed; caution should be taken on treating patients with low dose heparin or low molecular weight heparin for deep vein thrombosis (DVT) prophylaxis during treatment with bevacizumab as there may be an increased risk of bleedingXx_NEWLINE_xXPatients receiving warfarin anticoagulation, who cannot be transferred to other agents such as enoxaparin or dabigatran, and for whom anticoagulants cannot be held for up to 24 hours will be excludedXx_NEWLINE_xXPatients with thromboembolic disease cannot be on Coumadin, but low molecular heparins are allowedXx_NEWLINE_xXSUNITINIB MALATE ARM: Patients who require use of therapeutic doses of Coumarin-derivative anticoagulants such as warfarin are excluded; note: low molecular weight heparin is permitted provided the patient’s prothrombin time (PT) international normalized ratio (INR) is < 1.5Xx_NEWLINE_xXCoagulopathy, including the use of Coumadin or heparin anticoagulants that cannot be discontinued for the cryoablation procedure; NOTE: heparin for line patency without detectable lab abnormalities for coagulation will be allowedXx_NEWLINE_xXParticipants on any dose of warfarin or are on full dose anticoagulation with other agents including low molecular weight heparin, antithrombin agents, antiplatelet agents and full dose aspirin within 7 days prior to study enrollment; participants on prophylactic doses of low molecular weight heparin are allowedXx_NEWLINE_xXPatients must not be on any anticoagulationXx_NEWLINE_xXPatients must be able to take daily prophylactic anticoagulation medication, such as: aspirin (81 or 325 mg) warfarin, low molecular weight heparin, or other medications as clinically indicatedXx_NEWLINE_xXThe subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, thrombin or factor Xa inhibitors; aspirin (up to 325 mg/day), low-dose warfarin (=< 1 mg/day), prophylactic and therapeutic low molecular weight heparin (LMWH) are permittedXx_NEWLINE_xXUse of concomitant anticoagulation with warfarin or other vitamin K antagonists is prohibited, as is treatment with these agents in the 7 days prior to signing the ICD. The use of other anticoagulants (eg, heparins) and anti-platelet agents is allowed per investigator's discretion. Arm C only (CC-122 in combination with obinutuzumab):Xx_NEWLINE_xXAble to take required prophylactic anticoagulation.Xx_NEWLINE_xXConcurrent use of therapeutic warfarinXx_NEWLINE_xXAble to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to acetylsalicylic acid [ASA] may use warfarin or low molecular weight heparin)Xx_NEWLINE_xXAre receiving therapeutic anticoagulation with warfarin, low-molecular weight heparin, or similar agents. Participants receiving prophylactic, low-dose anticoagulation therapy are eligible provided that they are on low-molecular weight heparin or oral factor Xa inhibitors.Xx_NEWLINE_xXConfirmed acute lower extremity proximal DVT or PE for which long term treatment with low molecular weight heparin (LMWH) is indicated;Xx_NEWLINE_xXThe subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or Coumadin-related agents, thrombin or factor Xa (FXa) inhibitors, and antiplatelet agents (e.g., clopidogrel); low dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are permitted; therapeutic anticoagulation with LMWHs may be allowed in certain circumstancesXx_NEWLINE_xXProthrombin time (PT) >1.5 x ULN for subjects not on therapeutic vitamin K antagonists (phenprocoumon, warfarin)Xx_NEWLINE_xXInternational normalized ratio (INR) and partial thromboplastin time (PTT) =< 3.0 x UNL; NOTE: anticoagulation is allowed if target INR =< 3.0 x UNL on a stable dose of warfarin or on a stable dose of low molecular weight heparin for > 2 weeks at time of registrationXx_NEWLINE_xXAny condition requiring warfarin or thrombolytic anticoagulantsXx_NEWLINE_xXOngoing need for therapeutic anticoagulants (full dose heparin, warfarin, factor Xa or direct thrombin inhibitors; rivaroxaban, apixaban, dabigatran) chronic use of aspirin or anti-platelet agents (ticlopidine or clopidogrel)Xx_NEWLINE_xXConcurrent use of therapeutic warfarinXx_NEWLINE_xXIsolated CABG or single valve repair/replacements are allowed only if either (a) AT level is less than 80% OR (b) preoperative heparin is received (unfractionated heparin [UFH] for at least 12 hours; low- molecular-weight heparin [LMWH] for more than 5 days).Xx_NEWLINE_xXRequires anti-coagulation with warfarin or a vitamin K antagonist.Xx_NEWLINE_xXAble to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to acetylsalicylic acid [ASA] may use warfarin or low molecular weight heparin)Xx_NEWLINE_xXParticipants receiving therapeutic anti-coagulation or anti-platelet (anti-aggregant) therapies, except for therapeutic enoxaparin or low dose aspirin. Use of subcutaneous heparin prophylaxis, including low molecular weight heparin is also permittedXx_NEWLINE_xXPatients on full-dose anticoagulants (e.g., warfarin) with prothrombin time (PT) international normalized ratio (INR) > 1.5 are eligible provided that both of the following criteria are met:\r\n* The patient has an in-range INR (usually between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin\r\n* The patient has no active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)Xx_NEWLINE_xXPT INR > 1.5 unless the patient is on full-dose warfarinXx_NEWLINE_xXPatients receiving therapeutic doses of warfarinXx_NEWLINE_xXNo active anticoagulation within 7 days of study Day 1; including acetylsalicylic acid, low molecular weight heparin, or warfarin.Xx_NEWLINE_xXSubjects receiving heparin, warfarin, factor Xa inhibitors or other similar anticoagulants. Note: Subjects may be receiving low-dose aspirin and/or non-steroidal anti-inflammatory agents.Xx_NEWLINE_xXPatients who require anticoagulation should receive low-molecular weight or standard heparin and not warfarinXx_NEWLINE_xXCoagulation studies with prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) within normal limits (± 15%); if the patient is on Coumadin – we would switch the patient to low molecular weight (LMW) heparin product such as fondaparinaux (Arixtra) or enoxaprin (Lovenox); an anti-factor Xa test should be available demonstrating adequate anti-coagulation on the low molecular weight heparin (LMWH) (therapeutic range 0.4-0.8); however, if this is not possible then INR must be kept =< 3Xx_NEWLINE_xXRequires the use of warfarinXx_NEWLINE_xXBleeding or thrombotic disorders requiring anticoagulant therapy such as warfarin, or similar agents requiring therapeutic INR monitoringXx_NEWLINE_xXCurrent use of anticoagulants at therapeutic doses within 7 days prior to study drug administration. Prophylactic use of unfractioned heparin or low molecular weight heparin is permittedXx_NEWLINE_xXNo concurrent warfarin or Coumadin-derivativesXx_NEWLINE_xXPatients on anticoagulant therapy with unstable dose of warfarin and/or having an out-of- therapeutic range INR (> 3) within the 4 weeks prior to study entryXx_NEWLINE_xXCurrent use of therapeutic warfarin. NOTE: Low molecular weight heparin and prophylactic low-dose warfarin are permittedXx_NEWLINE_xXRequires therapeutic anticoagulation with warfarin at baseline; patients must be off warfarin or warfarin-derivative anti-coagulants for at least 7 days prior to starting study drug; however, therapeutic or prophylactic therapy with low-molecular weight heparin is allowed.Xx_NEWLINE_xXAble to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to acetylsalicylic acid [ASA] may use warfarin or low molecular weight heparin)Xx_NEWLINE_xXConcurrent use of therapeutic warfarinXx_NEWLINE_xXCoagulopathies - patients requiring full dose anticoagulation with warfarin are excluded, however, patients stable and on other anticoagulants can be included.Xx_NEWLINE_xXConcurrent use of warfarin or other vitamin K antagonistsXx_NEWLINE_xXCurrent use of therapeutic warfarin. Low-molecular-weight heparin and prophylactic low-dose warfarin are permittedXx_NEWLINE_xXConcurrent use of therapeutic warfarinXx_NEWLINE_xXSubjects receiving heparin, warfarin, or other similar anticoagulants. Note: Subjects may be receiving lowdose aspirin and/or non-steroidal anti-inflammatory agents.Xx_NEWLINE_xXTherapeutic anticoagulation (except for low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous device) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid < 325 mg per day)Xx_NEWLINE_xXPatient is currently receiving warfarin or other coumarin derived anti-coagulant, for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH), or fondaparinux is allowed.Xx_NEWLINE_xXAble to take anticoagulation, warfarin or equivalent agent, as detailed in the treatment planXx_NEWLINE_xXReceiving chronic anticoagulation therapy (e.g. warfarin, heparin) other than aspirinXx_NEWLINE_xXHistory of thromboembolic event or other condition requiring ongoing use of anticoagulation either with warfarin or low molecular-weight heparin. Note: Occlusion of a central line is not exclusion.Xx_NEWLINE_xXInternational normalized ratio (INR) and partial thromboplastin (PTT) =< 3.0 x ULN (anticoagulation is allowed if target INR =< 3.0 x ULN on a stable dose of warfarin or on a stable dose of low molecular weight [LMW] heparin for > 2 weeks at time of registration)Xx_NEWLINE_xXThe subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or factor Xa inhibitors or antiplatelet agents (e.g., clopidogrel); low dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day) and prophylactic low molecular weight heparin (LMWH) are permittedXx_NEWLINE_xXSubject is currently receiving or requires anticoagulation therapy (e.g., warfarin at any dose) or any drugs (e.g., aspirin, clopidogrel, etc.) or herbal supplements that affect platelet function, with the exception of low molecular weight heparin or heparin that are used to maintain the patency of a catheterXx_NEWLINE_xXPatients receiving treatment with vitamin K, Coumadin or other agents containing warfarin and heparin. Heparin flush to maintain patency of a central venous access device is allowed.Xx_NEWLINE_xXPatients who are on anticoagulation medication that may not be safely held for the procedure (>= 5 days for antiplatelet agents and warfarin; >= 24 hours for low-molecular weight heparin formulations) will be excludedXx_NEWLINE_xXCurrent treatment with warfarin sodium or any other Coumadin-derivative anticoagulantXx_NEWLINE_xXActive therapeutic anticoagulationXx_NEWLINE_xXPatients for whom prophylactic anticoagulation therapy (eg. 325mg aspirin PO daily or warfarin [Coumadin] 1-2 mg/day, or any other coumarin-derivative anticoagulants) is not an optionXx_NEWLINE_xXAble to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to acetylsalicylic acid [ASA] may use warfarin or low molecular weight heparin)Xx_NEWLINE_xXTherapeutic anticoagulation with vitamin-K antagonists (e.g., warfarin) or with heparins and heparinoids; NOTE: Prophylactic anticoagulation as described below is allowed:\r\n* Low dose warfarin (1 mg orally, once daily) with prothrombin time PT-INR =< 1.5 x ULN is permitted; subjects taking concomitant warfarin should be monitored regularly for changes in PT, PT-INR or clinical bleeding episodes\r\n* Low dose aspirin (=< 100 mg daily)\r\n* Prophylactic doses of heparinXx_NEWLINE_xXPatients may not be on anti-coagulants (warfarin, etc.) other than low-molecular weight heparin (LMWH)Xx_NEWLINE_xXThe subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or factor Xa inhibitors, or antiplatelet agents (e.g., clopidogrel); low dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are permitted (please note that there may be cases in which patients on study require anticoagulation for deep vein thrombosis [DVT]/pulmonary embolism [PE] management; this does not necessitate taking the patient off study)Xx_NEWLINE_xXTherapeutic anticoagulation with vitamin-K antagonists (e.g., warfarin) or with heparins and heparinoids; however, prophylactic anticoagulation as described below is allowed:\r\n* Low dose warfarin (1 mg orally, once daily) with prothrombin time (PT)-international normalized ratio (INR) =< 1.5 x ULN is permitted; infrequent bleeding or elevations in PT-INR have been reported in some subjects taking warfarin while on sorafenib or capecitabine therapy; therefore, subjects taking concomitant warfarin should be monitored regularly for changes in PT, PT-INR or clinical bleeding episodes\r\n* Low dose aspirin (=< 100 mg daily)Xx_NEWLINE_xXThe subject requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or warfarin-related agents, heparin, thrombin or factor xabans (Xa) inhibitors, or antiplatelet agents (eg, clopidogrel); low dose aspirin (=< 100 mg/day), low-dose warfarin (=< 1 mg/day), and prophylactic low molecular weight heparin (LMWH) are permittedXx_NEWLINE_xXWarfarin and its derivatives are not allowed; patient can be receiving low molecular weight heparin if clinically indicatedXx_NEWLINE_xXPatients on full dose anticoagulants or any dose of warfarin; patients on prophylactic dose of low-molecular weight or unfractionated heparin are allowed.Xx_NEWLINE_xXConcurrent use of systemic low molecular weight heparin or low dose warfarinXx_NEWLINE_xXPatients requiring therapeutic anticoagulation (e.g., warfarin, dabigatran, heparin, or low molecular weight heparins [Lovenox, dalteparin])Xx_NEWLINE_xXAble to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant of aspirin or at increased risk of venous thrombosis may use warfarin or low molecular weight heparin)Xx_NEWLINE_xXPatients who are currently taking therapeutic doses of warfarin sodium or any other Coumadin-derivative anticoagulantXx_NEWLINE_xXPatients on full-dose anticoagulants (e.g., warfarin) with prothrombin time (PT) international normalized ratio (INR) > 1.5 are eligible provided that both of the following criteria are met:\r\n* The patient has an in-range INR (usually between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin\r\n* The patient has no active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)Xx_NEWLINE_xXPT INR > 1.5 unless the patient is on full-dose warfarinXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5; (anticoagulation is allowed if target INR =< 1.5 on a stable dose of warfarin or on a stable dose of low molecular weight [LMW] heparin for > 2 weeks at time of study initiation)Xx_NEWLINE_xXFor those participants receiving warfarin (Coumadin), unfractionated heparin, or low-molecular weight heparin therapy, the applicable coagulation parameter that is being monitored must be within the accepted therapeutic ranges for those indications\r\n* Note: transfusions and/or growth factor dependent participants are not excluded if the above parameters can be achieved with such supportXx_NEWLINE_xXIs receiving prophylactic or therapeutic anticoagulation with warfarin or any other oral anticoagulantXx_NEWLINE_xXConcurrent or prior (within 7 days of enrollment) anticoagulation therapy, except for the use of low dose coumarin-type anticoagulants or low molecular weight heparin for prophylaxis against central venous catheter thrombosisXx_NEWLINE_xXAble to receive prophylactic anticoagulation with aspirin, warfarin or low molecular weight heparin when required for lenalidomide administrationXx_NEWLINE_xXCurrent use of therapeutic warfarin.Xx_NEWLINE_xXNo use of full dose, therapeutic anti-coagulation with warfarin or related anti-coagulants or unfractionated or low molecular weight heparins.Xx_NEWLINE_xXProthrombin time (PT) (international normalized ratio [INR]) > 1.5, unless the patient is on full dose anticoagulants; if so, the following criteria must be met for enrollment:\r\n* The subject must have an in-range INR (usually between 2-3) on a stable of low molecular weight heparin; anticoagulation with warfarin is not allowedXx_NEWLINE_xXPT-INR/PTT < 1.5 x upper limit of normal [Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists]. Low-dose aspirin is permitted (</= 100 mg daily).Xx_NEWLINE_xXAny condition requiring full-dose anticoagulants, such as warfarin, heparin, or thrombolytic agentsXx_NEWLINE_xXInternational normalized ratio (INR) < 1.5 (anticoagulation is allowed if target INR =< 1.5 on a stable dose of warfarin or on a stable dose of low molecular weight [LMW] heparin for > 2 weeks at the time of registration)Xx_NEWLINE_xXTherapeutic anticoagulationXx_NEWLINE_xXAble to take aspirin daily as prophylactic anticoagulation therapy (subjects intolerant to aspirin may use warfarin or low-molecular-weight heparin).Xx_NEWLINE_xXPatients on warfarin or plavixXx_NEWLINE_xXPatients receiving therapeutic anticoagulation should be switched to low molecular weight heparin (LMWH) before the first cycle of obinutuzumabXx_NEWLINE_xXAnticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon); Note: use of low molecular weight heparin (or any anticoagulation agent) is allowed provided there is no history of bleeding (minor or major) =< 12 months prior to registration; the treating physician should discuss the case with the study chairXx_NEWLINE_xXTreatment with warfarin or other vitamin K antagonists; patients who are on active treatment with warfarin or other vitamin K antagonists for conditions requiring anticoagulation will be switched, when not contraindicated, to a different form of anticoagulation, including low molecular weight heparin (LMWH)s (ex: enoxaparin, dalteparin) or oral anti-Xa drugs (ex: rivaroxaban or apixaban) Patients who switch to these alternative forms of anticoagulation will be eligibleXx_NEWLINE_xXPatients receiving warfarin anticoagulation, who cannot be transferred to other agents such as enoxaparin or dabigatran, and for whom anticoagulants cannot be held for up to 24 hours will be excludedXx_NEWLINE_xXTherapeutic anticoagulation with vitamin-K antagonists (e.g., warfarin) or with heparins and heparinoids; however, prophylactic anticoagulation as described below is allowed:\r\n* Low dose warfarin (1 mg orally, once daily) with PT-INR =< 1.5 is permitted; infrequent bleeding or elevations in PT-INR have been reported in some subjects taking warfarin while on regorafenib therapy; therefore, subjects taking concomitant warfarin should be monitored regularly for changes in PT, PT-INR or clinical bleeding episodes\r\n* Low dose aspirin (=< 100 mg daily)\r\n* Prophylactic doses of heparinXx_NEWLINE_xXIf currently not on anticoagulation medication, willing and able to take aspirin (325 mg) daily; note: if aspirin is contraindicated, the patient may be considered for the study after if on therapeutic dose warfarin or low molecular weight heparin; patients unable to take any prophylaxis are not eligibleXx_NEWLINE_xXCurrently receiving antiplatelet therapy of prasugrel or clopidogrel, or full dose anticoagulation treatment with therapeutic doses of warfarin; Note: treatment with low doses of warfarin (e.g., =< 2 mg/day ) for line patency allowed; also, low molecular weight heparins, fondaparinux, antiaggregation agents (e.g., eptifibatide, epoprostenol, dipyridamole) or locally accepted low doses of acetylsalicylic acid (up to 100 mg daily) may be administered concomitantly with dovitinib with cautionXx_NEWLINE_xXPatient is currently receiving warfarin or other Coumarin derived anti-coagulant, for treatment, prophylaxis or otherwise; therapy with heparin, low molecular weight heparin (LMWH), or fondaparinux is allowedXx_NEWLINE_xXProthrombin time/international normalized ratio (PT INR) < 1.4 for patients not on warfarin confirmed by testing within 14 days prior to registration; patients on full-dose anticoagulants (e.g., warfarin or low molecular weight [LMW] heparin) must meet both of the following criteria:\r\n* No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)\r\n* In-range international normalized ratio (INR) (between 2.5 and 3.5) on a stable dose of warfarin-based oral anticoagulant; or on a stable dose of low molecular weight heparin; or INR between 1.5 and 2 if a Greenfield filter is in placeXx_NEWLINE_xXConcomitant treatment with any of the following drugs: azathioprine, cyclophosphamide, cyclosporine, pirfenidone, full dose anticoagulation (vitamin K antagonists, dabigatran, heparin), fibrinolysis and high dose anti-platelet therapy (ex. Plavix 150 mg); prophylactic low dose heparin, heparin flush for maintenance of intravenous devices, prophylactic use of anti-platelet therapy (e.g. acetyl salicylic acid up to 325 mg/d, clopidogrel 75 mg/d, or equivalent doses) should be allowedXx_NEWLINE_xXPatients on fibrinolysis, full-dose therapeutic anticoagulation, or high dose antiplatelet therapyXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 ULN unless on warfarin therapy (investigator would need to determine if safe for participant to stop warfarin prior to surgery and warfarin therapy)Xx_NEWLINE_xXUse of Coumadin (warfarin) or other vitamin-K antagonists for anticoagulation; non-Coumadin anticoagulation is permittedXx_NEWLINE_xXRequires anticoagulation with warfarin or equivalent vitamin K antagonists (e.g., phenprocoumon)Xx_NEWLINE_xXPatients on full dose anticoagulants (e.g., warfarin or LMW heparin) must meet both of the following criteria:Xx_NEWLINE_xXLow molecular weight heparin or Novel oral anti-coagulant: stable dose within 14 days prior to registrationXx_NEWLINE_xXThrombologic event within 3 weeks of treatment start date, unless stable on anticoagulation with low molecular weight heparin (LMWH) or Factor Xa inhibitor for at least 2 weeksXx_NEWLINE_xXCurrent or recent use of dipyridamole, ticlopidine, clopidogrel, cilostazol is excluded; aspirin (=< 325 mg per day) is allowed; prophylactic anticoagulation with oral or parenteral anticoagulants for the patency of venous access devices or other indications is allowed, therapeutic use of low-molecular weight heparin (such as enoxaparin), and factor Xa inhibitors are allowed; use of warfarin is prohibitedXx_NEWLINE_xXCurrent use of warfarin or other anticoagulantsXx_NEWLINE_xXUse of WarfarinXx_NEWLINE_xXReceiving warfarin at registrationXx_NEWLINE_xXTherapeutic anticoagulation (except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous devise) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid < 325 mg per day)Xx_NEWLINE_xXCurrent use of American ginseng, ramelteon, or warfarinXx_NEWLINE_xXWeight of < 205 kgsXx_NEWLINE_xXWeight of < 205 kgsXx_NEWLINE_xXDiagnosis of symptomatic venous thromboembolism requiring therapeutic-dose anticoagulation (unfractionated or low-molecular weight heparin or oral anticoagulants) throughout the period of hematopoietic recoveryXx_NEWLINE_xXUse of anticoagulant agent (warfarin, Coumadin, Jantoven, Marevan, Lawarin, Waran, or Warfant)Xx_NEWLINE_xXPatients must not take MAO-Inhibitors for 14 days before registration or any time during study treatment; concomitant therapy with heparin and warfarin is also not permitted at registrationXx_NEWLINE_xXNo therapeutic heparin (including low molecular weight) or Coumadin useXx_NEWLINE_xXTherapeutic anticoagulation with vitamin-K antagonists (e.g., warfarin) or with heparins and heparinoids; however, prophylactic anticoagulation as described below is allowed: 1. low dose warfarin (1 mg orally, once daily) with prothrombin time [PT]-INR =< 1.5 x ULN is permitted; subjects taking concomitant warfarin should be monitored regularly for changes in PT, PT-INR or clinical bleeding episodes; we will monitor the PT/INR weekly for patients on warfarin and liver function test every 2 weeks (total bilirubin, and AST (serum glutamic oxaloacetic transaminase [SGOT]) and ALT (serum glutamic pyruvic transaminase [SGPT]) if hepatic metastases are present or if patients are on potentially hepatoxic agents such as acetaminophen or statins; 2. low dose aspirin (=< 100 mg daily); and 3. prophylactic doses of heparinXx_NEWLINE_xXDocumented venous thromboembolism while on therapeutic anticoagulation (“anticoagulation failure”)Xx_NEWLINE_xXKnown bleeding disorders or taking any dose of warfarin or heparinXx_NEWLINE_xXConcomitant treatment with full dose warfarin (coumadin) is NOT allowed; however, treatment with low molecular weight heparin (LMWH) (such as enoxaparin or dalteparin) or rivaroxaban is allowed; patients on full dose warfarin (coumadin) must be transitioned to either LMWH or rivaroxaban prior to administration of any study related drugsXx_NEWLINE_xXAnticoagulation with warfarinXx_NEWLINE_xXConcomitant use of warfarin or other vitamin K antagonistsXx_NEWLINE_xXPatients who require warfarin or other vitamin K antagonists for anticoagulation (other anticoagulants are allowed after consultation with the principal investigator)Xx_NEWLINE_xXAre being treated with warfarin anticoagulation therapyXx_NEWLINE_xXTherapeutic dose anticoagulation with warfarin, low molecular-weight heparin, or similar agents.Xx_NEWLINE_xXWeight > 110kgXx_NEWLINE_xXPatient is using warfarin or any other Coumadin-derivative anticoagulant or vitamin K antagonists; patients must be off warfarin-derivative anticoagulants for at least seven days prior to starting the study drug; low molecular weight heparin is allowed; patients with congenital bleeding diathesis are excludedXx_NEWLINE_xXPatients on vitamin K antagonist (i.e., warfarin)Xx_NEWLINE_xXPatients receiving vitamin K antagonist (warfarin)Xx_NEWLINE_xXPatients on vitamin K antagonist warfarinXx_NEWLINE_xXKnown bleeding disorders or taking any dose of warfarin or heparinXx_NEWLINE_xXFemales of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS® program; able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to acetylsalicylic acid [ASA] may use warfarin or low molecular weight heparin)Xx_NEWLINE_xXKnown coagulopathy or taking heparin (including low molecular weight heparin) at full anti-coagulation doses (prophylaxis is allowed) or Coumadin at any dose; patients on aspirin or non-steroidal anti-inflammatories or other antiplatelet medicines will be allowed to participateXx_NEWLINE_xXCurrent oral steroid use or receiving daily therapeutic anticoagulation (e.g. Coumadin, Lovenox)Xx_NEWLINE_xXIf taking antiplatelet or anticoagulation medication, it must be able to be discontinued prior to the procedure for an appropriate amount of time (e.g., aspirin, ibuprofen, low molecular weight heparin preparations)Xx_NEWLINE_xXKnown coagulopathy or taking heparin (including low molecular weight heparin) at full anti-coagulation doses (prophylaxis is allowed) or Coumadin at any dose; patients on aspirin or non-steroidal anti-inflammatories or other antiplatelet medicines will be allowed to participateXx_NEWLINE_xXCurrently prescribed anti-coagulation medications (ReoPro [abciximab], Aggrenox [aspirin plus dipryridamole], Persantine [dipyridamole], Integrillin [eptifibatide], Ticlid [ticlopidine], Aggrastat [terofiban], Heparin, Coumadin [warfarin], Pradaxa [dabigatran], Xarelto [rivaroxaban])Xx_NEWLINE_xXReceiving WarfarinXx_NEWLINE_xXDocumented venous thromboembolism while on therapeutic anticoagulation (“anticoagulation failure”)Xx_NEWLINE_xXUse of anticoagulation medications, including but not limited to coumadin, warfarin, plavixXx_NEWLINE_xXWomen on anticoagulationXx_NEWLINE_xXHistory of allergic reactions attributed to heparin or low molecular weight heparinXx_NEWLINE_xXReceived any type of pharmacologic thromboprophylaxis (e.g. low molecular weight heparin or heparin) for > 48 hours during current hospitalizationXx_NEWLINE_xXEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Requirement for anticoagulation with warfarin or other vitamin K antagonists (concomitant use of other anticoagulants is permitted)Xx_NEWLINE_xXChronic anti-coagulation with warfarin; patients on low molecular weight heparin or fondaparinux may be enrolledXx_NEWLINE_xXUse of any anticoagulation medications, such as warfarin or CoumadinXx_NEWLINE_xXConcurrent use of anticoagulants (i.e. Coumadin/warfarin)Xx_NEWLINE_xXCurrent or planned use of anticoagulant drugs such as: warfarin, heparin, low molecular weight heparin, Plavix, or Aggrenox throughout the course of the studyXx_NEWLINE_xXHistory of therapeutic doses of anticoagulants including warfarin and low molecular weight heparin (e.g. for prior deep venous thrombosis and pulmonary embolisms) in the preceding yearXx_NEWLINE_xXWarfarin is not permittedXx_NEWLINE_xXObtained within 28 days prior to registration: Activated partial thromboplastin time (aPTT) =< 1.5 x ULN (unless on prophylactic or therapeutic dosing with low molecular weight heparin)Xx_NEWLINE_xXPatients with an active bleeding diathesis or on oral anti-vitamin K medication (except low-dose warfarin used for catheter-related thrombosis prophylaxis)Xx_NEWLINE_xXFor patients undergoing a research only biopsy: requirement for anticoagulation with heparin, low molecular weight heparin, clopidogrel, rivaroxaban, dabigatran, apixaban, warfarin, aggrenox, fondaparux, ticagrelor, etc (aspirin and other nonsteroidal antiinflammatory drugs [NSAIDs] are ok but should be held prior to biopsy in accordance with institutional standard of care)Xx_NEWLINE_xXInability to stop anticoagulants (e.g., heparin, Warfarin) or antiplatelet agents (e.g. aspirin, clopidogrel) prior to procedureXx_NEWLINE_xXPatients who require warfarin or other vitamin K antagonists for anticoagulation (other anticoagulants are allowed)Xx_NEWLINE_xXInternational normalized ratio (INR) < 1.5, unless patient is on therapeutic anticoagulation where a therapeutic INR is acceptable; anticoagulation with low molecular weight heparin or warfarin, where medically indicated, is permitted*Xx_NEWLINE_xXCurrent treatment with anticoagulation such as warfarin or low-molecular-weight heparin.Xx_NEWLINE_xXUse of antibiotics, antiplatelets (e.g. clopidogrel), or anticoagulants (e.g. warfarin) within the last 3 monthsXx_NEWLINE_xXNo use of full dose, therapeutic anti-coagulation; however, low dose warfarin for catheter prophylaxis or acetylsalicylic acid are acceptableXx_NEWLINE_xXActive therapeutic anticoagulationXx_NEWLINE_xXOngoing therapy with any anticoagulant or antiplatelet agents (example, aspirin, clopidogrel, heparin, or warfarin).Xx_NEWLINE_xXAnticoagulation: if currently receiving therapeutic anticoagulation with heparin, low-molecular weight heparin, or Coumadin, not eligibleXx_NEWLINE_xXThe patient requires therapeutic doses of any anticoagulant, including LMWH. Concomitant use of warfarin, even at prophylactic doses, is prohibited.Xx_NEWLINE_xXAny condition requiring warfarin or thrombolytic anticoagulantsXx_NEWLINE_xXOngoing therapy with any anticoagulant or antiplatelet agents (example, aspirin, clopidogrel, coumadin, heparin, or warfarin) that cannot be held to permit tumor biopsy).Xx_NEWLINE_xXNo antiplatelet or anticoagulation medications allowed within 7 days prior to talimogene laherparepvec injection except low-dose heparin needed to maintain venous catheter patency.Xx_NEWLINE_xXAdequate blood clotting as defined by international normalized ratio (INR) and activated partial thromboplastin time (aPTT) ? 1.5 times ULN (patients on anticoagulation with an agent such as warfarin or heparin or rivoraxaban will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists). For patients on warfarin, close monitoring of at least weekly evaluations will be performed until INR is stable based on a measurement at pre-dose, as defined by the local standard of careXx_NEWLINE_xXRequire therapeutic use of anticoagulation medicationsXx_NEWLINE_xXRequires anticoagulation with warfarin or other vitamin K antagonistsXx_NEWLINE_xX